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BACKGROUND 
Pain is a significant public health problem.  Chronic pain alone affects approximately 100 
million U.S. adults.  ―Pain reduces quality of life, affects specific population groups disparately, 
costs society at least $560-635 billion annually (an amount equal to about $2,000 for everyone 
living in the United States), and can be appropriately addressed through population health-level 
interventions.‖1  According to the American Academy of Pain Medicine, pain affects more 
Americans than diabetes, heart disease and cancer combined.  The chart below depicts the 
number of chronic pain sufferers compared to other major health conditions.
2 
 
 
 
 
 
Drugs that were initially developed to treat chronic pain, which is often debilitating and 
devastating, are now too often misused.  The statistics associated with prescription drug misuse 
and abuse are staggering.
3
  In fact, this abuse has led the national Centers for Disease Control 
and Prevention to classify prescription drug abuse as a national epidemic.
4
 
National Statistics 
It is difficult to comprehend the number of Americans who have misused prescription 
drugs.
5
  In 2011, 52 million people in the United States, over the age of 12, had used prescription 
drugs non-medically in their lifetime, over six million of those in the past month.
6
  In 2010 alone, 
an estimated 2.4 million Americans used prescription drugs non-medically for the first time, on 
average approximately 6,600 new users a day.
7
 
Unfortunately, prescription drug abuse has been increasing at an alarming rate for the 
past decade.  Between 1991 and 2010, prescriptions for stimulants increased from 5 million to 
Condition Number of Sufferers Source 
Chronic Pain 100 million Americans Institute of Medicine of The National 
Academies 
Diabetes 25.8 million Americans 
(diagnosed and estimated 
undiagnosed) 
American Diabetes Association 
Coronary Heart Disease 
(heart attack and chest pain) 
Stroke 
16.3 million Americans 
7.0 million Americans 
American Heart Association 
Cancer 11.9 million Americans American Cancer Society  
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nearly 45 million and for opioid analgesics from 75.5 million to 209.5 million.
8
  And, sadly, 
based on the abuse and dependency statistics, this drug use does not appear to be limited to one 
occasion for many Americans.  According to the National Survey on Drug Use and Health, 1.9 
million people in the United States meet abuse or dependence criteria for prescription opioids 
alone.
9
 
 
Based on the prescribing patterns in the United States, however, this epidemic is not 
altogether surprising.  Astonishingly, enough prescription painkillers were prescribed in the 
United States in 2010 to medicate every American adult every four hours for one month.
10
  In 
2013, 207 million prescriptions were written for prescription opioid pain medications.
11
  And, 
while the United States has only 5% of the world’s population, its citizens consume 75% of the 
world’s prescription drugs.12 
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This epidemic comes with real consequences, including tragic consequences for families 
and communities and increased costs to the healthcare and criminal justice systems.  In 2012, 
drug overdose was the leading cause of injury death in the United States.
13
  Among people 25 to 
64 years old, drug overdose deaths exceed those caused by motor vehicle accidents.
14
  And, as a 
corollary to the increased prescription drug abuse over the past decade, drug overdose deaths 
have increased by 117% from 1999 to 2012.
15
  In 2011, 1.4 million Americans visited an 
emergency department due to prescription drug use or abuse.
16
  A 2011 study estimated the total 
cost in the United States of nonmedical use of prescription opioids was $53.4 billion, with $42 
billion attributable to lost productivity, $8.2 billion to criminal justice costs, $2.2 billion to drug 
abuse treatment, and $944 million to medical complications.
17
 
 S.C. State Plan to Prevent and Treat Prescription Drug Abuse – December 2014 4 
 
 
 
Perhaps the most troublesome component of this epidemic is the extent to which it affects 
two of our most vulnerable populations.  Youth and older adults are at particular risk for 
prescription drug abuse.
18
  Abuse of prescription drugs is highest among young adults aged 18 to 
25, with 5.9% reporting non-medical use in the past month.
19
  Among youth aged 12 to 17, 3% 
reported non-medical use in the past month.
20
  And according to these youth, more than half of 
them were given these drugs by a friend or relative.
21
  Of all people misusing or abusing 
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prescription drugs, 70% report obtaining them from a friend or relative either for free, by 
purchase, or by stealing them.
22
  Essentially, home medicine cabinets become a repository of 
drugs when leftover prescription drugs are not properly discarded. 
South Carolina 
South Carolina is not immune from this epidemic.  In 2011, South Carolina ranked 23
rd
 
highest per capita in both opioid painkiller prescriptions and overdose deaths;
23
 however, many 
in South Carolina believe even this number is understated due to inconsistent and incomplete 
reporting of these deaths in previous years.  Between July 1, 2013, and June 30, 2014, 354 adult 
deaths attributable to prescription poisoning occurred in our state.  This total includes 281 deaths 
that were ruled accidental overdoses and 51 ruled suicides.  The balance of those cases involved 
6 underdetermined cause of death and 16 with other factors contributing to the cause of death.  
During this same period, one accidental prescription drug overdose involving a minor occurred.  
In addition to prescription overdose deaths, South Carolina has also seen an increase in the 
number of deaths attributable to heroin.  From July 1, 2013, through June 30, 2014, 31 deaths 
involving heroin occurred in South Carolina.  There have been more reported overdose deaths 
from prescribed opioids than heroin, cocaine and methamphetamine combined.
24
 
South Carolinians have created a significant demand upon resources for the treatment of 
opioid abuse, including inpatient admissions, emergency department visits, observation 
discharges, and outpatient visits to the South Carolina Department of Mental Health in acute 
care, long-term acute care and inpatient rehab facilities.  Between July 1, 2011, and July 1, 2013, 
a total of 10,490 patients generated 12,947 visits relating to the treatment of opioid abuse.
25
  
According to the South Carolina Department of Alcohol and Other Drug Abuse Services 
(DAODAS), 687 patients were admitted to its programs alone with a primary diagnosis of opiate 
abuse or dependence in 2004.  That number has consistently increased, rising to 2,011 patients 
admitted to DAODAS programs with a primary diagnosis of opiate abuse or dependence in 
2013.  Similarly, 925 patients were admitted with a diagnosis of any opiate abuse or dependence 
in 2004. 2,968 patients with this diagnosis were admitted in 2013. 
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These statistics regarding overdose deaths and treatment interventions are high, but are 
dwarfed when compared to the volume of pills actually prescribed and dispensed in our state.  
According to data collected by DHEC, from July 1, 2013, through June 30, 2014, 1,226,159 
patients received 4,211,181 prescriptions for opioids.  As a result of those prescriptions, 
272,818,351 opioids were dispensed.  569,843 patients in South Carolina obtained 2,611,458 
prescriptions for benzodiazepines during this same time frame, resulting in the dispensing of 
157,508,374 benzodiazepines.
26
  As shown in the chart below, South Carolina ranks in the 
highest quartile for painkiller prescriptions per person. 
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Of the 24,082 South Carolina licensees with prescriptive authority, 20,101 have DHEC 
registrations authorizing the prescription of controlled substances in South Carolina.  Only 21% 
of those prescribers who hold a DHEC registration are also registered with the Prescription 
Monitoring Program (PMP).  Further, those who are registered with the PMP performed only 
309,852 queries between July 1, 2013, and June 30, 2014.
27
 
Call to Action 
While grim, there is hope that the Governor, the Legislature, the healthcare community, 
regulatory and enforcement agencies, the treatment community, and other stakeholders can work 
together to curb the tide of prescription drug abuse in our state.  Responding to this epidemic will 
require comprehensive action, a long-term commitment, and coordinated efforts on the state and 
local level.  Unquestionably, the healthcare community has one of the most vital roles in the 
fight. 
Other states have paved the way, including New York, Florida, Tennessee, Utah, 
Kentucky, Maryland, and Ohio, having successfully implemented strategies in their states with 
positive outcomes.  Following in their footsteps, South Carolina now must embark upon the 
journey to fight this epidemic in our state. 
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INTRODUCTION 
In May 2013, South Carolina’s Inspector General published a report, attached to at 
Appendix A, highlighting the fact that South Carolina lacked a statewide strategy to address 
prescription drug abuse for the many South Carolinians who struggle with this issue.  In 
response, on March 14, 2014, Governor Haley signed Executive Order No. 2014-22, attached as 
Appendix B, establishing the Governor’s Prescription Drug Abuse Prevention Council (Council).  
The Council is comprised of representatives from each agency with a regulatory, enforcement or 
treatment role in this issue, including the South Carolina Law Enforcement Division (SLED); 
South Carolina Department of Health and Environmental Control (DHEC); South Carolina 
Department of Labor, Licensing and Regulation (LLR); South Carolina Board of Dentistry; 
South Carolina Board of Medical Examiners; South Carolina Board of Nursing; South Carolina 
Board of Pharmacy; a South Carolina Solicitor’s Office; South Carolina Department of Health 
and Human Services (DHHS); South Carolina Department of Alcohol and Other Drug Abuse 
Services (DAODAS); and a South Carolina coroner.  The Council was charged with the 
following:  1) to analyze available data to determine the extent of prescription drug abuse in 
South Carolina; 2) to develop a comprehensive state plan (Plan) to proactively combat and 
prevent drug abuse in South Carolina; 3) to assist and encourage local communities to engage 
existing coalitions or to establish new coalitions to combat prescription drug abuse; and, finally 
4) to continue to meet as a Council and at least annually report the progress of the Council’s 
efforts.  Significantly, the Council’s efforts mark the first time in South Carolina’s history that 
policy makers and stakeholders on a statewide level have assembled to begin the difficult task of 
addressing this issue. 
To accomplish the objectives set forth in the Governor’s Order, the Council met on 
numerous occasions, solicited input from a number of stakeholders and contacted numerous 
legislators to educate and garner support for its efforts.  The Council also reviewed State Plans 
from at least six other states as well as relevant academic and evidence-based literature.  Finally, 
several members of the Council traveled to Washington, D.C., to a work session entitled 
―Advancing Policy and Practice: A 50 State Working Meeting to Prevent Opioid-Related 
Overdose,‖ sponsored by the United States Department of Health and Human Services.  At this 
meeting, Council members were able to meet with representatives from federal agencies and 
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other states that have successfully tackled this issue and spent several days planning the best 
approach to implement these strategies in our state. 
Throughout this process, three things have become abundantly clear to the Council.  One, 
chronic and acute pain are very real concerns for many South Carolinians, and any statewide 
plan must allow healthcare professionals to retain the professional judgment to prescribe 
controlled substances for treatment of these legitimate medical conditions.  Two, the South 
Carolina Reporting and Identification Prescription Tracking System (SCRIPTS) (also known as 
the Prescription Monitoring Program or PMP) administered by DHEC is the state’s most 
valuable resource in addressing this issue and is central to the prevention of prescription drug 
abuse.  Three, an adequate surveillance system is vital to ensure that all prevention and 
intervention efforts are evidence based.  It was discovered that many state and county agencies 
have data that is relevant to this issue, but the state’s approach to collecting and mining this data 
has been fragmented and oftentimes inconsistent and/or incomplete.  To gain a clearer 
understanding of the data that currently exists and to address gaps in data, the Council formed a 
Data Committee.  The ongoing work of the committee will ensure that going forward South 
Carolina will more accurately measure the problem and hopefully the state’s successes in 
reducing prescription drug abuse.  The Council’s Plan was written in light of these three 
considerations. 
Ultimately, the Council’s work culminated in this Plan.  Specifically, the Plan designates 
eight key priority areas:  (1) Prescribers; (2) South Carolina Prescription Monitoring Program; 
(3) Pharmacy; (4) Third-Party Payer; (5) Law Enforcement; (6) Treatment; (7) Education and 
Advocacy; and (8) Data and Analysis.  The Plan contains over 50 recommendations, some of 
which propose legislative amendments.  These priorities are consonant with the 
recommendations contained in the National Governor’s Association, ―Strategies for Reducing 
Prescription Abuse.‖  The Council believes that these recommendations will provide clear, easy- 
to-understand guidance to prescribers; will unite regulatory, treatment and enforcement efforts; 
and ultimately, will reduce prescription drug abuse in our state. 
This Plan simply marks the beginning of the Council’s efforts.  The Council will continue 
its work over the next months and years to oversee the implementation of the recommendations, 
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to measure the effectiveness of the state’s efforts, and to make further recommendations based 
on measurable outcomes.  The Council understands that several of these recommendations will 
have a fiscal impact that has yet to be analyzed, and those recommendations are denoted as such 
within the Plan.  As the work of the Council progresses, the fiscal impact will be analyzed.  
Ideally, the benefits to the state in reduced healthcare and criminal justice costs and human 
suffering will outweigh the costs of implementation.  It is the hope of the Council that its efforts, 
in conjunction with our many partners and stakeholders, will ultimately reduce the devastating 
emotional and economic effects suffered by so many South Carolinas as a result of prescription 
drug abuse. 
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PRIORITY AREA:  PRESCRIBERS 
Perhaps no other group in the state has a bigger role to play in combating prescription 
drug abuse than prescribers.  The Council acknowledges that chronic and acute pain and other 
medical conditions are very real concerns for many South Carolinians.  The Council strongly 
believes that healthcare professionals (i.e., licensed physicians, dentists, and physician assistants 
and advanced practice nurses with prescriptive authority working under the supervision of 
physicians and/or dentists) must retain the professional judgment to prescribe controlled 
substances for treatment of these legitimate medical conditions.  However, the rate of 
prescribing, abuse and dependency, and deaths related to prescription drugs have dramatically 
increased over the past decade, with no end in sight.  With only 21% of controlled substance 
prescribers enrolled in the SCRIPTS program, a powerful tool in ferreting out drug abuse and 
misuse, certainly more can be done.  As gatekeepers of the prescription pad, and thus the supply 
of prescription drugs in our state, controlled substance prescribers must partner with the Council 
to combat this abuse. 
I. Education and Advocacy 
Healthcare professionals are trained to assist and heal their patients.  This duty can 
present a dilemma for those professionals faced with treating a patient with a substance abuse 
disorder.  Some prescribers may be simply naïve regarding certain patients’ drug-seeking 
behavior, either due to lack of training on the issue, failure to use the tools available to them to 
detect this behavior, or lack of time to address the issue in today’s competitive healthcare 
market.  Further, because of the prescribers’ desire to treat and heal, it may be difficult to tell 
their patients ―no.‖  Finally, many prescribers receive little formal education on this topic and 
may not be well versed in what to do when presented with a patient with a substance use 
disorder.  And, given the state’s low registration and utilization rates of SCRIPTS, healthcare 
professionals are either unaware of its existence or of the program’s clinical benefits.  The 
Council believes that most prescribers, once further educated, will be better equipped to more 
often utilize the tools at their disposal to identify patients who may be drug seekers, to more 
conservatively prescribe controlled substances, and to treat patients with addiction issues. 
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To that end, Act 244 was passed during the previous legislative session, mandating that 
all physicians complete as part of their annual continuing education requirement at least two 
hours related to approved procedures for prescribing and monitoring controlled substances listed 
in Schedules II, III, and IV of the schedules provided for in Sections 44-53-210, 44-53-230, 44-
53-250, and 44-53-270.  By statute, this education must be provided by:  1) a statewide 
organization recognized by the Accreditation Council for Continuing Medical Education to 
recognize and accredit organizations in South Carolina offering continuing medical education; or 
2) a statewide organization approved to provide continuing medical education by its national 
organization that is accredited by the Accreditation Council for Continuing Medical Education. 
The South Carolina Board of Medical Examiners (Medical Board) has committed to 
meeting with stakeholders to discuss the implementation of this continuing education mandate 
for physicians. 
Recommendation:  The Council recommends that the Medical Board, the South Carolina 
Department of Health and Environmental Control, and other stakeholders work together to 
create a suggested list of topics for the education providers to include in the mandated training. 
Recommendation:  The Council recommends extending the education mandate contained in Act 
244 to dentists, physician assistants, and advanced practice nurses with prescriptive authority. 
While Act 244 mandated this education for physicians, it did not mandate education for 
the other types of prescribers in our state – dentists, physician assistants, and advanced practice 
nurses with prescriptive authority.  For the same reasons that the education is beneficial for 
physicians, it would be beneficial to all controlled substance prescribers. 
Recommendation:  The Council recommends working with schools to increase course offerings 
related to this topic or make it a mandatory part of curriculum. 
One study found that, on average, medical students receive only 12 hours of education 
related to pain and pain management.
28
  In South Carolina, there are several schools that train 
prescribers, and the Council recommends partnering with the schools, outlined below, to increase 
course offerings. 
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 Medical Schools – Medical University of South Carolina, University of South 
Carolina School of Medicine, University of South Carolina School of Medicine 
Greenville, Edward Via School of Osteopathic Medicine 
 Dental – Medical University of South Carolina College of Dental Medicine 
 Physician Assistants – Medical University of South Carolina 
 Advance Practice Nurses – Clemson University, University of South Carolina, 
Medical University of South Carolina, Francis Marion University 
II. Clinical Guidance 
It is critical that prescribers have clear clinical guidance that sets forth the appropriate 
treatment of pain to assist them in safely prescribing certain controlled substances.  The Council 
acknowledges, however, that this clinical guidance should come from the South Carolina Boards 
of Medical Examiners, Dentistry, and Nursing (Boards) as the public bodies responsible for 
regulating prescribers in our state.  Accordingly, the Council requested that the Board of Medical 
Examiners revise its Pain Management Guidelines, which were originally published in July of 
2009, to offer clear guidance to prescribers on how to safeguard South Carolinians’ access to 
pain care while combating drug misuse, abuse, diversion and addiction. 
In order to facilitate input from the medical community at large, the Council formed a 
work group composed of physicians from various practice areas, licensed dentists and members 
of the treatment community.  This work group offered valuable insight and recommendations for 
the Board of Medical Examiners’ consideration in formulating appropriate revisions.  Using the 
work product of this group, the Board of Medical Examiners has now issued Revised Pain 
Management Guidelines (Revised Guidelines) that are attached to the Plan as Appendix A.  
These Revised Guidelines were unanimously endorsed by both the Board of Dentistry and the 
Board of Nursing.  The Council appreciates the hard and expedient work of the Boards to 
provide this important guidance to prescribers. 
The Revised Guidelines are intended to alleviate prescriber uncertainty and to encourage 
patient-centered pain care.  All prescribers should become knowledgeable about assessing 
patients’ pain and effective methods for treatment of this pain, as well as statutory requirements 
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for prescribing controlled substances.  Prescribers must recognize that an individual’s use of 
opioid analgesics for non-legitimate medical purposes poses a significant threat to the health and 
safety of the individual, as well as to the public.  Further, prescribers must recognize that 
inappropriate prescribing of controlled substances may contribute to drug misuse and diversion 
by individuals who seek opioids for non-legitimate purposes.  Accordingly, based on the Revised 
Guidelines the Council anticipates that all prescribers will incorporate safeguards into their 
practices to minimize the risk of misuse, abuse, and diversion of opioid analgesics and other 
controlled substances.  The consensus of the Boards and the Council is that utilization of 
SCRIPTS, the state’s prescription drug monitoring program, prior to prescribing opiates is the 
best safeguard against these risks and the best practice for prescribers. 
The Council recommends the following related to the Revised Guidelines: 
Recommendation:  The Council strongly encourages all prescribers to be familiar with the 
Revised Pain Management Guidelines contained in Appendix A to this Plan and to conform their 
prescribing practice to these Revised Guidelines. 
Recommendation:  The Council recommends that prescribers be knowledgeable about all state 
and federal laws and regulations regarding controlled substances. 
In order to dispense or administer controlled substances, the prescriber must be registered 
with the U.S. Drug Enforcement Administration (DEA), licensed by the state in which he or she 
practices, and compliant with applicable federal and state regulations.  Prescribers are referred to 
the Practitioner’s Manual of the DEA for specific rules and regulations governing the use of 
controlled substances; relevant provisions of the South Carolina Dental Practice Act, the South 
Carolina Medical Practice Act, and the South Carolina Nurse Practice Act; relevant regulations 
promulgated by the regulatory authorities governing these professions; and advisory opinions 
issued by the regulatory authorities governing these professions. 
Recommendation:  The Council recommends that registration and utilization of SCRIPTS be 
considered mandatory for prescribers to determine the appropriate controlled substance 
prescribing dosages, if any, to provide safe, adequate pain management and to protect the 
prescribers from inappropriate prescribing situations 
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Recommendation:  The Council recommends that prescribers who prescribe chronic opioid 
therapy be familiar with treatment options for opioid addiction, including those available in 
licensed opioid treatment programs and those offered by an appropriately credentialed and 
experienced physician through office-based opioid treatment, so as to make appropriate 
referrals when needed. 
Recommendation:  The Council recommends prescribers treating patients with controlled 
substances consider prescribing Naloxone when clinically indicated. 
Patients prescribed more than 80 mg Morphine Equivalent Dose (MED) are at an 
increased risk of death from respiratory depression.  The level of 80 mg MED should be 
considered an extreme, potentially unsafe therapeutic limit.  Overdoses may occur at lower 
dosages.  The 80 mg MED is not to be considered the upper limit of safe prescribing, but rather 
an alert limit to warn of possible increased risks of unsafe dosage levels, especially in narcotic 
naïve patients.  Assessment of risk stratification for narcotic abuse and misuse should be 
performed at levels below 80 mg MED to be ensure appropriate clinical behavior.  These patients 
require closer monitoring, and other respiratory depressants, such as alcohol and 
benzodiazepines, should be avoided.  The Council and the Boards recognize that a prescription 
of Naloxone may be appropriate for patients in certain situations who are prescribed high-dose 
opioids or are more vulnerable to the risk of opioid overdose due to co-morbidities or other 
factors. 
Recommendation:  The Council strongly encourages the Boards of Medical Examiners, 
Dentistry, and Nursing to continue to update the Revised Pain Management Guidelines as 
lessons are learned and when data suggests that changes are needed. 
III. State Agency Collaboration 
In addition to the regulatory boards charged with the responsibility of regulating the 
prescribers licensed to practice in South Carolina, the DHEC Bureau of Drug Control (BDC) 
plays a significant role in the regulation of prescriptive behavior.  The Council and the respective 
boards responsible for regulating prescribers jointly recommend the following collaboration 
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between the South Carolina Department of Labor, Licensing and Regulation (LLR), the Boards 
and the BDC: 
Recommendation:  SCRIPTS must be as user friendly as possible to facilitate easy use. 
When possible, online registration capability may facilitate greater registration and 
utilization of the South Carolina Reporting and Identification Prescription Tracking System 
(SCRIPTS).  To that end, DHEC may benefit from access to certain information in LLR’s 
possession for the sole purpose of license and credential verification of prescribers. The Council 
and the Boards recommend that LLR and DHEC collaborate to identify and share the 
information necessary to expedite online SCRIPTS registration. 
Recommendation:  The BDC and Boards have a shared interest in correcting improper 
prescribing behaviors, through education when possible and enforcement when necessary. Upon 
establishment of criteria by the Board of Medical Examiners, which may include, but are not 
limited to, a MED threshold and prescription volume by prescriber, SCRIPTS shall generate 
reports by which outlier prescribers will be identified for further review by the BDC and, if 
necessary, referral to LLR for initiation of the complaint process. 
Recommendation:  Based on the Revised Guidelines, the Council recognizes that patients 
requiring more than 80 MED present an increased risk of death from respiratory depression. 
Accordingly, the Council recommends that, when capable, SCRIPTS offer an MED calculator 
that can generate an alert for each patient whose record is accessed and for which the MED 
exceeds 80 MED. The MED calculator and alert function will provide an additional tool for the 
prescriber to utilize when assessing a patient’s prescriptive needs. This threshold is not a 
substitute for a prescriber’s clinical judgment, but merely one factor for consideration in the 
prescribing process.  
Recommendation:  The BDC shall utilize the full analytical capabilities of SCRIPTS to identify 
prescribers engaged in questionable prescribing activities. 
Recommendation:  Information shared between LLR and DHEC may be used to assist the BDC 
in promptly identifying a prescriber’s area of specialization, if applicable, when investigating a 
licensee’s prescribing behavior. 
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Recommendation with Potential Fiscal Impact:  The Council and the Boards support the 
compilation and distribution of report cards to all South Carolina licensed prescribers so that 
each prescriber can see how his or her prescribing patterns compare to other prescribers 
practicing in the same or similar clinical setting.  
Such a report card will be private and communicated directly to the prescriber by DHEC. 
The purpose of the report card is solely to facilitate the prescriber’s self-evaluation of his or her 
prescribing patterns.  The report card will not be used for any regulatory purpose, including 
discipline by the respective licensing board should the prescriber become the subject of a 
disciplinary action.  Although it is unclear whether the current SCRIPTS vendor can provide 
prescriber report cards, it is likely that this capability can be developed with the allocation of 
additional resources.  The Council and the Boards respectfully recommend that DHEC, through 
SCRIPTS, work to develop this valuable tool that will prove useful for self-assessment purposes. 
Recommendation:  Prescribers engaged in prescribing conduct not rising to the level of 
criminal activity, but who may benefit from additional education or counseling regarding 
appropriate prescribing, shall be identified by the BDC and provided an educational 
intervention. 
Once identified, the BDC inspector responsible for initiating contact with such a 
designated prescriber shall provide the prescriber a list of professional resources, to be identified 
by the Boards, that may counsel the prescriber in question about the prevailing prescribing 
practice standards in his or her respective profession.  For example, if a dentist is identified by 
the BDC as a prescriber of concern, he or she will be provided a list of dentists approved by the 
Board of Dentistry who have volunteered to serve as mentoring resources.  Communication with 
these volunteer mentors will be voluntary and will only occur at the prescriber’s initiation.  No 
educational intervention will prevent the BDC or the respective regulatory authorities from fully 
investigating and prosecuting improper or illegal prescribing patterns of a licensed prescriber. 
Recommendation:  Prescribers identified by the BDC engaged in conduct rising to the level of 
criminal activity, shall be subjected to the standard process of investigation by BDC, arrest, 
where appropriate, and referral to LLR for investigation of unprofessional conduct. 
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Recommendation:  The Council recommends that the Boards identify licensees with expertise in 
ethical prescribing to serve as hearing officers or hearing panel members in any disciplinary 
cases arising from prescribing behavior.  These designated individuals shall hear and review 
disciplinary matters and make recommendations to the applicable regulatory board for final 
action as set forth in each profession’s Practice Act and regulations.  These individuals shall not 
be the same licensees identified to serve as voluntary mentors. 
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PRIORITY AREA: SOUTH CAROLINA PRESCRIPTION 
MONITORING PROGRAM 
The Bureau of Drug Control (BDC) at the Department of Health and Environmental 
Control (DHEC) administers South Carolina’s prescription drug monitoring program.  This 
centralized database, known as SCRIPTS (South Carolina Reporting and Identification 
Prescription Tracking System), allows authorized users access to data concerning the dispensing 
of controlled substances.  It is intended to improve the state’s ability to identify and stop 
diversion of prescription drugs in an efficient and cost-effective manner that will not impede the 
appropriate medical utilization of licit controlled substances where there is a valid prescriber-
patient or pharmacist-patient relationship. 
The SCRIPTS database includes all retail and outpatient hospital pharmacy dispensing of 
Schedules II, III, and IV controlled substances.  It also includes dispensing activity of those 
controlled substances into the state of South Carolina by non-resident pharmacies.  Dispensers 
that are exempt from reporting to SCRIPTS are:  Veterans Affairs facilities, most long-term care 
and assisted-living facilities, methadone clinics, emergency departments dispensing less than a 
48-hour supply of controlled substances, or veterinary offices dispensing less than a five-day 
supply. 
SCRIPTS is accessible 24 hours a day, seven days a week.  The SCRIPTS technology 
was upgraded in January 2014 to allow dispensers to report daily, rather than monthly.  This 
transition to more frequent reporting enables prescribers to have access to more current 
information in SCRIPTS reports, as data is updated daily.  A SCRIPTS report provides the 
Schedules II, III, and IV controlled substance prescriptions a patient has had filled in a specified 
period, as well as the prescriber and the dispenser of the prescriptions.  The report should be used 
to supplement a patient evaluation, to confirm a patient’s drug history, or to document 
compliance with a therapeutic regimen. 
South Carolina currently exchanges prescription monitoring program data with 17 other 
states through the National Association of Boards of Pharmacy’s Prescription Monitoring 
Program Interconnect hub.  Although none of our border states are participating in interstate data 
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sharing, we continue to have open communication with them to encourage them to join the hub 
for interstate sharing.  All non-resident pharmacies that dispense controlled substances into our 
state were required to register with the BDC by October 31, 2014, or they may be subject to 
enforcement action. 
In 2014, the South Carolina Legislature passed Act 244 to require dispensers to report 
daily to DHEC.  The act extends access to authorized delegates, and requires at least two hours 
of continuing medical education on prescribing and monitoring controlled substances in 
Schedules II, III, and IV to be used toward the total number of continuing medical education 
requirements for physicians.  The SCRIPTS database is scheduled to make the technological 
upgrades to allow the registration of authorized delegates by Spring 2015.  Also, the SCRIPTS 
patient report will be enhanced to include a daily MED. 
While technological upgrades to SCRIPTS and advancements in health policy have 
furthered the objectives of the prescription monitoring program, SCRIPTS remains underutilized 
by prescribers.  The following recommendations are suggested to increase access to and 
utilization of the prescription monitoring program. 
I. Required Enrollment in SCRIPTS 
Recommendation:  The Council recommends that prescriber registration and enrollment in 
SCRIPTS become required and recommends that each patient’s prescription history is reviewed 
in certain circumstances prior to the prescription of controlled substances. 
South Carolina should require:  (1) universal prescriber enrollment in SCRIPTS; and (2) 
utilization of SCRIPTS to check patients’ prescription-dispensing histories before prescribing 
controlled substances in certain circumstances.  There should be careful consideration of 
exceptions to the mandatory utilization requirement for certain prescribers, such as oncologists 
who are treating patients at end of life.  Under the current voluntary conditions, less than 25% of 
prescribers enroll in SCRIPTS and a smaller proportion of those enrolled actually utilize the 
program.  The prescription monitoring program must be fully utilized by prescribers to most 
effectively combat prescription drug abuse and diversion. 
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As of June 2014, 22 states had legislation mandating that prescribers and in some cases 
dispensers use the prescription monitoring program in certain circumstances:  Arizona, Colorado, 
Delaware, Indiana, Kentucky, Louisiana, Massachusetts, Minnesota, Mississippi, Nevada, New 
Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Rhode Island, Tennessee, 
Vermont, Virginia, Washington, and West Virginia.
29
  Experiences in Kentucky, Tennessee, and 
New York, for example, indicate that statutory mandates rapidly increased enrollment and 
utilization of prescription monitoring programs, resulting in decreased doctor shopping and 
prescribing of certain controlled substances.  Florida imposed other requirements with similar 
results. 
 
http://www.cdc.gov/VitalSigns/opioid-prescribing/ 
II. Analytics Tool 
Recommendation with Potential Fiscal Impact:  The Council recommends that DHEC 
proceed to acquire analytic services and/or products to work with SCRIPTS data, expanding the 
capacity to develop predictive models and to detect anomalies in prescriber patterns and patient 
prescription behaviors.  The Council further recommends that DHEC send letters notifying 
prescribers of suspicious behavior identified by the analytics. 
SCRIPTS could be more effectively used as an analytic tool with advanced technological 
enhancements.  Staff in the BDC currently complete the analysis of the prescription monitoring 
program data manually to identify patterns of suspicious behavior.  Advanced technological 
enhancements to SCRIPTS would allow more efficient and thorough analysis of the prescription 
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monitoring program data.  By December 2014, DHEC will have advanced analytic, risk 
compliance, and fraud software.  DHEC should use this capability to efficiently detect anomalies 
in prescribing patterns and patient behaviors by incorporating, among other information, the 
advisement of clinical professionals and widely accepted prescribing guidelines to determine 
predictive models and business rules to guide decision-making when contemplating enforcement 
action. 
III. Data Sharing 
Recommendation with Potential Fiscal Impact:  The Council recommends that DHEC 
coordinate real-time hosting of data from other state agencies to include, but not be limited to, 
the South Carolina Department of Alcohol and Other Drug Abuse Services; South Carolina 
Department of Mental Health; South Carolina Department of Juvenile Justice; South Carolina 
Department of Social Services (DSS); South Carolina Department of Health and Human 
Services (DHHS); South Carolina Attorney General’s Office; South Carolina Department of 
Probation, Parole, and Pardon Services; South Carolina Department of Corrections; South 
Carolina Prosecution Commission; and the South Carolina Law Enforcement Division. 
Addressing prescription drug abuse in the state is a coordinated effort between DHEC 
and other state agencies.  As data sharing with other state agencies is currently limited to manual 
transmission, DHEC, the Attorney General’s Office, DHHS and DSS have coordinated to create 
improved efficiencies and coordination of real-time data sharing between the agencies.  
Additional real-time data from other agencies should be included to maximize program integrity. 
Recommendation with Potential Fiscal Impact:  The Council recommends that DHEC and the 
Revenue and Fiscal Affairs Office collaborate and create capacity for information sharing 
between SCRIPTS and the South Carolina Health Information Exchange (SCHIEx). 
The SCRIPTS database should be integrated with the SCHIEx web application to allow 
prescribers to log in to SCHIEx and access a patient’s medical history while simultaneously 
viewing a patient’s controlled substance prescription history, without having to log in to separate 
websites.  As successfully achieved in Indiana, integrating data from the prescription monitoring 
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program and the health information exchange would streamline workflow for prescribers and 
improve accessibility, as well as SCRIPTS utilization. 
IV. Integration of SCRIPTS Reports in Electronic Health Records 
Recommendation with Potential Fiscal Impact:  The Council recommends that DHEC work 
with prescribers and healthcare providers to integrate SCRIPTS data into electronic health 
records, so that access to patients’ controlled substance records does not interrupt prescriber 
workflow. 
SCRIPTS staff have been working to identify opportunities to integrate SCRIPTS data 
directly into the clinical workflow of prescribers through electronic health records (EHRs).  
SCRIPTS was awarded a grant from the federal Substance Abuse and Mental Health Services 
Administration to financially assist in these efforts.  Discussions are currently underway with 
prospective healthcare systems that are interested in participating in this endeavor.  By 
integrating SCRIPTS data into EHRs, providers will be able to more easily and quickly access a 
patient’s controlled substance record without interrupting their clinical workflow.  This ease of 
use and time savings should greatly increase provider use of SCRIPTS reports in clinical 
decision making.  This knowledge will allow them to make better prescribing and treatment 
decisions, decreasing prescription misuse and abuse. 
V. Interconnectivity Between States  
Recommendation:  The Council recommends that Governor Haley request by letter the States 
of North Carolina and Georgia enroll in the National Association of Boards of Pharmacy’s 
Prescription Monitoring Program Interconnect hub to afford enhanced regional monitoring.  
Although a total of 18 states are currently enrolled in the Interconnect hub, neither of 
South Carolina’s bordering states participate.  This presents an obstacle to effective prescription 
drug monitoring, especially within the counties along South Carolina’s border. 
 S.C. State Plan to Prevent and Treat Prescription Drug Abuse – December 2014 24 
 
VI. Education and Advocacy 
Recommendation:  The Council recommends that the BDC continue and expand initiatives to 
coordinate education and awareness campaigns for SCRIPTS, to include outreach to more 
stakeholders such as provider associations, licensing boards, and investigative agencies. 
The BDC has also launched an awareness campaign with active prescribers as identified 
by the SCRIPTS database, addressed with educational approaches through onsite visits and 
inspections, and recruited for enrollment in the prescription monitoring program.  Staff members 
continue to make strides by collaborating with provider associations, licensing boards, and 
investigative agencies to provide educational presentations that explain the value and functions 
of accessing and utilizing SCRIPTS reports.  It is recommended that BDC staff members 
continue and expand initiatives to coordinate education and awareness campaigns to include 
outreach to more stakeholders. 
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PRIORITY AREA:  PHARMACY 
I. Take-Back Programs 
Recommendation with Potential Fiscal Impact:  The Council recommends expanding 
prescription drug take-back programs across the state. 
Take-back programs are an important part of any strategy to reduce supply and 
inappropriate access to prescription drugs.  Because pharmacists constitute one of the most 
accessible healthcare professionals, coupled with the fact that they dispense medications, these 
professionals should be an integral part of any take-back program.  The Secure and Responsible 
Drug Disposal Act of 2010 was passed in an effort to curtail prescription drug abuse by 
authorizing regulations that outline methods for ultimate users to dispose of their unused or 
unwanted pharmaceutical controlled substances.  The U.S. Drug Enforcement Administration’s 
Final Rule implementing the Secure and Responsible Drug Disposal Act took effect October 9, 
2014, and now authorizes pharmacies and hospitals/clinics with on-site pharmacies to voluntarily 
maintain collection receptacles for unused prescription drugs.  Because pharmacies are in the 
unique role of being readily accessible by the public, the Council recommends that these newly 
authorized venues volunteer to comply with federal regulations, and become certified collectors 
of unused and expired prescription drugs.   
The Council recommends that successful programs that currently exist such as the ones 
listed in the Law Enforcement section be replicated in all counties within South Carolina.  
Coordination of law enforcement at the state, county, and local municipal level with pharmacies 
and healthcare facilities should be initiated and expanded.  The South Carolina Sheriff’s 
Association – in coordination with the professional pharmacy organization – should search for 
funding to advertise and facilitate expansion of these programs. 
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II. Non-Resident Entities 
Recommendation:  The Council recommends regulating non-resident entities dispensing 
controlled substances into the state. 
Any licensed healthcare facility that is located in the state and dispenses controlled 
substances must register with the Department of Health and Environmental Control (DHEC)’s 
controlled substance division.  This registration serves as an accountability mechanism for 
facilities within the state.  For example, if a facility violates the controlled substance laws of 
South Carolina (including SCRIPTS reporting), the registration can be disciplined and even 
revoked.  As of October 31, 2014, this registration now includes non-resident facilities 
dispensing controlled substances into the state. 
III. Increase SCRIPTS Registrations 
Recommendation:  The Council recommends increasing the number of pharmacists registered 
to use SCRIPTS. 
When looking at the successes of other state prescription drug abuse programs, it is 
evident that those state’s prescription drug monitoring programs are the cornerstone.  As shown 
in the Inspector General’s report, pharmacists have been slow to register for this important tool.  
Educational programs by the professional organizations and in conjunction with DHEC should 
be conducted to allow for tutorials and Q&A sessions.  As stated earlier, facilities located in the 
state that dispense controlled substances must register with DHEC.  All pharmacists must seek 
initial licensure and renew that license with the Department of Labor, Licensing and Regulation 
(LLR) on an annual basis.  LLR and the Board of Pharmacy should work with DHEC to allow 
registration with SCRIPTS at the time of initial licensure application or renewal.  There should 
be a question about SCRIPTS registration on the license renewal and a link to the SCRIPTS 
registration site.  
 S.C. State Plan to Prevent and Treat Prescription Drug Abuse – December 2014 27 
 
IV. Electronic Submission of Controlled Substance Prescriptions 
Recommendation:  The Council recommends that the professional boards and associations 
work with practitioners, pharmacies, and software vendors to encourage electronic transmission 
for all classes of controlled substance prescriptions. 
Recently, the DEA and DHEC have amended their regulations to allow for electronic 
prescriptions for controlled substances.  An electronically submitted prescription reduces the risk 
of diversion and prescription fraud.  Many prescribers are now electronically submitting 
prescriptions for Schedule III, IV, and V drugs.  The updated regulations, however, require 
prescribers, pharmacies and software vendors to have additional security measures in order to 
transmit prescriptions for Schedule II medications, and generally, in South Carolina, prescribers, 
pharmacies, and software vendors lack the requisite updates.  Thus, almost universally in our 
state, Schedule II drugs are being prescribed on paper with the prescriber’s original signature.  
The council recommends that the professional boards and associations work with practitioners, 
pharmacies and software vendors to encourage compliance with these updated regulations to 
facilitate electronic transmission of Schedule II drugs. 
 
 
 
 
 
 
 
 
 S.C. State Plan to Prevent and Treat Prescription Drug Abuse – December 2014 28 
 
PRIORITY AREA:  THIRD-PARTY PAYER 
The prescription abuse and fraud-related costs to a medium-sized health insurer were 
estimated to be over $42 million a year, and could exceed $70 billion to all health insurers – 
private and public.
30
  Thus, healthcare payers have an incentive and a unique opportunity to drive 
efforts to address opioid overuse and abuse in South Carolina.  Payer policy can be used to 
influence prescriber requirements, behavior, and practice.  Once prescribers contract to receive 
payment for services from a third-party payer, they necessarily agree to certain conditions that 
must be met for payment.  While some of the recommendations by the Council require statutory 
changes, several of those changes can be accomplished, in part, though payer conditions.  For 
commercial payers, the Council can only make suggestions to implement certain payer 
conditions.  For Medicaid providers, however, the South Carolina Department of Health and 
Human Services (DHHS) can move forward with implementing certain payer conditions.  In 
South Carolina, a large number of opiod prescribers are enrolled to receive Medicaid 
reimbursement.
31
   
In addition, third-party payers can require beneficiaries to comply with certain conditions 
in order to qualify for coverage.  Again, the Council can only make suggestions to commercial 
payers to implement certain conditions.  DHHS can move forward now with implementing 
certain conditions of participation for over 1 million Medicaid beneficiaries.
32
  
Importantly, in considering the role of healthcare payers in addressing this issue, it must 
be noted that a key limitation of relying on payer policy is that it can be easily circumvented by 
not submitting claims for opioids to an insurance carrier.  Thus, it is important to leverage payer-
centric strategies that can address opioid overuse without simply driving individuals to pay cash 
for opioid medications. 
I. Policy Adjustment 
Recommendation:  The Council recommends that third-party payers adjust payer policies in 
accordance with the Revised Pain Management Guidelines outlined in the Prescriber section 
above and attached as Appendix A. 
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For instance, payers could require prescribers to check SCRIPTS in order to be 
reimbursed for a visit where certain controlled substances are prescribed.  And, through the post-
pay audit process, payers could ensure that treatment goals and plans, informed consent 
documents, and proper medical charting are documented to establish the requisite medical 
necessity of treatment of certain chronic pain to justify reimbursement. 
II. Claims Analytics With Accompanying Intervention 
Recommendation:  The Council recommends that third-party payers continue to adopt and 
revise interventions to address controlled substance misuse and abuse by beneficiaries, including 
participation in multi-agency data sharing with the Bureau of Drug Control Prescription 
Monitoring Program. 
Third-party payers currently perform complex analytical evaluations of claims data to 
detect patterns that suggest misuse or abuse by beneficiaries.  Once detected, payers employ 
various interventions to prevent further misuse or abuse.  Two general types of interventions 
currently used are as follows: 
 ―Lock-In‖ Policy:  Lock-in policies require that identified individuals get all 
medications from a single pharmacy provider.  This allows for greater coordination 
and eliminates the ability to ―pharmacy shop.‖ 
 Prescriber Information Programs:  These efforts look to retrospectively inform 
prescribers of potential overuse behaviors exhibited by their patients. 
Payers should continue to use opioid prescribing and dispensing data to identify aberrant 
behavior, develop means of predicting likely drug overuse, and ultimately adopt an assortment of 
additional policy interventions where appropriate.  One such suggestion is to include referrals to 
substance abuse treatment services as part of lock-in policies. 
III. Driving Evidence-Based Prescribing Through Utilization Management Techniques 
Recommendation:  The Council recommends that third-party payers adapt pharmacy benefits 
packages to encourage appropriate use of opioids. 
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The lack of generally accepted prescribing guidelines has resulted in a high degree of 
variation in the utilization management requirements of opioids, including dosage and day 
supply limits and prior authorization requirements. 
Efforts by the Council and the Boards to foster the development of statewide guidelines 
for the use of opioids in non-malignant pain, such as the Revised Pain Management Guidelines, 
should be adopted by payers to design utilization parameters that are consistent with evidence-
based medical practice.  Additional guidance regarding the use of opioids in special populations 
(pregnant women, upon emergency room discharge, etc.) should also be developed by 
appropriate clinical organizations and adopted by healthcare payers to ensure appropriate 
utilization. 
IV. Coverage of Screening and Treatment for Opioid Dependence or Addiction 
Recommendation with Potential Fiscal Impact:  The Council recommends healthcare payer 
coverage for screening and treatment for substance use disorders. 
Coverage of screening for opioid abuse and treatment is inconsistent among healthcare 
payers.  These inconsistencies are at least partially the result of the lack of generally accepted 
clinical guidance regarding the role of these services.  Statewide guidance regarding the coverage 
of opioids abuse screening and treatment, using validated methods such as the Screening, Brief 
Intervention, and Referral to Treatment process, should be developed and implemented by 
payers, and these guidelines should form the basis for the coverage of these items by healthcare 
payers. 
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PRIORITY AREA:  LAW ENFORCEMENT 
I. Take-Back Programs 
Recommendation with Potential Fiscal Impact:  The Council recommends expanding law 
enforcement sponsorship of prescription drug take-back programs. 
Presently, several law enforcement agencies throughout the state are involved in take-
back programs but are in the minority.  The following locations are permanent prescription drop 
off locations: 
 Anderson County Sheriff’s Office – 305 Camson Road, Anderson 
 Clover Police Department – 112 Bethel Street, Clover 
 Fort Mill Police Department – 111 Academy Street, Fort Mill 
 Greenville Law Enforcement Center - 4 McGee Street, Greenville 
 Greer Police Department - 102 S. Main Street, Greer 
 Horry County Police Department – 2560 N. Main Street, Conway 
 Lexington County Sheriff’s Department – 521 Gibson Road, Lexington 
 Richland County Sheriff’s Department - 5623 Two Notch Road, Columbia 
 Rock Hill Police Department – 120 E. Black Street, Rock Hill 
 Spartanburg County Sheriff’s Office (lobby) - 8045 Howard Street, 
Spartanburg 
 Tega Cay Police Department – 7705 Tega Cay Drive, Tega Cay 
 Winthrop Campus Police Department – 523 Myrtle Drive, Rock Hill 
 York County Sheriff’s Office – 1675-2A York Highway, York 
 York Police Department – 12 N. Roosevelt Street, York33 
The South Carolina Law Enforcement Division (SLED) can work with sheriffs and police 
chiefs throughout the state, the South Carolina Sheriffs’ Association, and the South Carolina 
Police Chiefs Association to encourage expanded take-back programs.  Funding for these boxes 
could be secured through public safety grants that are applied for yearly through the South 
Carolina Department of Public Safety. 
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II. Awareness and Education 
Recommendation:  The Council recommends increasing awareness and education of law 
enforcement to identify potential misuse of prescription drugs. 
Law enforcement in South Carolina has required annual in-service training along with 
federal and state education opportunities on a variety of subjects.  An increase in prescription 
drug awareness through training can be facilitated by the South Carolina Criminal Justice 
Academy, along with the United States Drug Enforcement Administration’s training department.  
Both of these agencies regularly tailor training to the needs of individual counties and states.  
The Council and SLED recommend a yearly increase in this type of training.  That training 
would vary by audience, depending on whether the training was directed at uniformed line 
officers or drug investigators.  Training for both groups is recommended. 
Further, expanding or changing some of the curricula used by school resource officers to 
better deal with school-age children and teens should be a focus.  This affected group has seen a 
continuous increase in exposure and use for the past 10 years. 
III. Community-Based Prevention 
Recommendation:  The Council recommends increasing law enforcement participation in 
community-based prevention programs. 
There are numerous community-based prevention programs that focus on opioid abuse.  
Most, if not all, include representation from law enforcement.  Once the Council launches a 
statewide campaign in designated areas of the state to form individual groups or coalitions, law 
enforcement agencies could use personnel from their community action units to participate.  
Their participation would include providing statistical information on arrests for pharmaceutical-
related crimes, prevention, and other ways to make the individuals aware of pharmaceutical drug 
abuse and how it negatively affects their communities. 
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IV. Expanded Investigation and Prosecution Efforts 
Recommendation with Potential Fiscal Impact:  The Council recommends continuing and 
expanding investigation and prosecution efforts specific to prescription drug diversion. 
The main goal for the prosecution aspect is to educate prosecuting agencies and to raise 
awareness of the issues caused by prescription drug abuse.  All state prosecuting agencies attend 
an annual Solicitor’s Conference for required legal training and updates.  The statewide 
prevention and education campaign should be presented at this conference.  While local resource 
limitations may prevent assigning an assistant solicitor to exclusively prosecute prescription drug 
crimes, solicitors will be encouraged to designate one prosecutor to prosecute all of the 
prescription drug cases in the office/judicial circuit.  Having designated prosecutors will allow 
the cases to be treated uniformly and in accordance with the Plan. 
Training will be sought in conjunction with law enforcement to focus prosecution efforts 
on ―prescription drug rings‖ rather than focusing on individuals.  Ideally, prescription drug 
prosecutors will attend training with local law enforcement representatives.  Grants can be 
sought both for training and for potential funding of a prosecutor position. 
The South Carolina Prosecution Commission will be approached about coordinating the 
collection of statistical information regarding prescription drug prosecutions statewide.  This will 
be accomplished by identifying the ―codes‖ for all related or pertinent crimes. 
V. Define Statutory Amounts 
Recommendation:  The Council recommends that law enforcement agencies and prosecutors 
work together to propose to the Legislature defined statutory amounts of opioids and other 
Schedule I through V controlled substances to qualify for the charges of Possession, Possession 
with the Intent to Distribute (PWID), and Trafficking. 
Currently, there are no defined limits in statute regarding the charges of Possession, 
PWID, or Trafficking in Schedule I through V controlled substances.  Setting limits or specifying 
the number of prohibited controlled substance dose units for each of these three charges would 
create uniformity with other drug charges in South Carolina that are set out by designated 
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prohibited amounts (i.e., one gram or less, 10 grams to 28 grams, etc.).  And, defining the 
necessary amounts of a PWID charge will create an inference rather than a per se violation in 
accordance with PWID charges for illicit drugs. 
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PRIORITY AREA:  TREATMENT 
The basic tenets of these recommendations are based on evidence that availability and 
appropriate delivery of treatment services, including medication, can arrest the course of 
addiction to prescription opioids and other opiates, which is a substance use disorder (SUD). 
Prescription opiate dependence is associated with dramatic costs to society, including lost 
productivity, social disorder, and increased healthcare utilization.  Successful treatment leads to 
substantial improvements in a number of areas, including reduction of drug use, increased 
personal health and social function, and reduction in threats to public health and safety.  As with 
other chronic disorders, continuing care and recovery support services are essential to 
maintaining improvements gained during SUD treatment.  Despite this fact, addictions are often 
viewed as acute conditions; and as such, acute-care procedures, such as detoxification, are 
sometimes considered appropriate and definitive treatments.  Access to a full continuum of care, 
including long-term continuing care options, is essential for an optimally functioning treatment 
system.  Because of insurance restrictions and funding limitations, many patients receive only 
detoxification or acute stabilization, with no support for continuing care. 
However, even when treatment is available and affordable, denial of problems associated 
with substance use is a core feature of addictions, and the stigma associated with addictions and 
addictions treatment can prevent people from seeking much-needed care. 
Overcoming these barriers to treatment will depend on education and accurate 
information about the benefits and risks of treatment, and on directly addressing the stigma 
associated with methadone, buprenorphine, and other pharmacological interventions.  Effective 
medication- assisted treatment does not cure SUDs, yet it is an extremely efficacious treatment 
for opioid addiction as a medical disorder when administered in conjunction with comprehensive 
services such as behavioral health counseling, case management, and treatment for co-occurring 
disorders.  In turn, it reduces the incidence and severity of harm that occurs to the untreated 
individual, his or her family, and the community.  Standards of treatment should be based upon 
clinical indications developed by the United States Substance Abuse and Mental Health Services 
Administration. 
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I. Medication-Assisted Treatment 
Recommendation with Potential Fiscal Impact:  The Council recommends expanding 
medication-assisted treatment (MAT) services for prescription opioid dependency and addiction, 
and integrating MAT and medication management services with recovery support services, and 
therapeutic interventions for substance use disorders, so that both are available to all 
individuals as conditions indicate. 
Methadone is an opiate agonist that was originally developed for the treatment of opioid 
dependence in the mid-1960s.  Methadone’s dramatic efficacy in reducing heroin use, decreasing 
crime, and improving mortality rates made it a pro-social and lifesaving intervention for 
countless opioid-dependent persons.  Methadone maintenance treatment (MMT) for opioid 
dependence in the United States is provided at clinics that are regulated by the Drug 
Enforcement Administration and the Center for Substance Abuse Treatment.  Patients initially 
attend the clinic six or seven days per week (some clinics are routinely closed on Sundays) to 
receive a supervised dose of methadone, typically delivered in a flavored liquid form.  While in 
the clinic, the patient may be asked to provide a urine sample for drug testing, have minor 
medical problems addressed, and/or attend an individual or group counseling session.  MMT 
provides a context in which a number of pro-social activities and health issues can be addressed.  
Studies have clearly demonstrated that MMT can be highly effective, using outcomes of 
treatment retention and rates of illicit opioid use (e.g., as measured by urine testing).  In addition, 
MMT is associated with decreases in criminal activity, decreases in illicit income, and decreases 
in non-opioid illicit drug use. 
Buprenorphine is a mixed agonist-antagonist opioid that was approved in 2000 for the 
treatment of opiate dependence.  A formulation of buprenorphine containing naloxone (initially 
marketed under the trade name Suboxone as a tablet, now available as a soluble film) is 
commonly used.  Naloxone is an opioid antagonist that will precipitate opioid withdrawal if 
injected by a person who is physically dependent upon typical agonist opioids (e.g., heroin, 
oxycodone).  The inclusion of naloxone in buprenorphine tablets and soluble film is a 
pharmacological strategy to decrease parenteral misuse of buprenorphine.  While sublingual 
naloxone has poor bioavailability, injected naloxone has good bioavailability.  As such, there is 
 S.C. State Plan to Prevent and Treat Prescription Drug Abuse – December 2014 37 
 
no naloxone effect if the buprenorphine/naloxone is taken as indicated (sublingually), but if the 
combination is dissolved and injected by an opioid-dependent person, the person will experience 
precipitated opioid withdrawal.  In contrast to methadone, a physician in an office-based setting 
in the United States can prescribe buprenorphine for the treatment of opioid dependence.  In 
2000, the Drug Addiction Treatment Act marked the beginning of a process designed to allow 
qualified physicians to prescribe approved narcotic drugs for the treatment of opioid dependence 
in office-based settings.  There are a number of approved training programs in place to teach 
physicians about the use of buprenorphine. There is a limit to the number of patients a physician 
can concurrently treat with buprenorphine (30 in the first year, and then up to 100 in subsequent 
years after requesting this increase).  This is the first time in modern medicine that physicians 
practicing in a variety of clinical settings, including office-based practice, are able to adequately 
treat opioid dependence with pharmacotherapy.  Hopefully, this will greatly increase access to 
treatment for opioid-dependent individuals; however, the number of physicians in South Carolina 
who are qualified to prescribe buprenorphine is limited. 
II. Coordination of Treatment and Pain Management 
Recommendation:  The Council recommends coordinating substance use disorder treatment 
services with co-occurring, clinically substantiated pain-management needs. 
Opioids are an effective and appropriate intervention for pain, and are used in many cases 
of chronic pain management.  The benefits of opioid therapy coexist with risks that patients may 
develop a dependency on the drug(s).  Patients and prescribers are best served with full 
knowledge of these risks and mechanisms to eliminate or mitigate them.  Extreme caution should 
be taken to ensure that those who truly need opioid therapy receive it without barriers.  
Monitoring and proper precautions should be taken with all people who are prescribed opioids.  
Elsewhere in this report, education programs and public awareness initiatives aim to address the 
significant lack of knowledge regarding risk of dependency and SUDs among prescribers and 
patients. 
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III. Referral Protocols 
Recommendation:  The Council recommends establishing a protocol for primary care 
practitioners to refer cases of prescription drug addiction to treatment, and establishing a 
protocol for treatment providers to refer and navigate individuals to primary care. 
As the prescribing professionals encounter evidence of SUDs, they should have 
knowledge of and access to accredited alcohol and other drug treatment programs.  Conversely, 
treatment programs should have or should develop a seamless referral process to primary care or 
other appropriate professional healthcare providers.  This bilateral referral process should exist in 
every community in South Carolina.  Furthermore, steps should be taken to expand access to 
treatment for SUDs and mental health concerns by building and expanding integrated health 
settings and medical homes.  The Department of Alcohol and Other Drug Abuse Services should 
address existing barriers such as transportation, literacy, geography, income, and availability, and 
propose solutions that erode or eliminate the barriers to both behavioral health and primary 
health care.  The use of telecommunications for services such as tele-medicine linkages and 
consults, and tele-recovery capacity using mobile devices, is an example of a solution that can 
overcome barriers. 
IV. Family Involvement 
Recommendation:  The Council recommends providing family education and services, inclusive 
of substance use disorder treatment and recovery services. 
Service to individuals in need of treatment is necessary but insufficient.  Family 
education and services must be available when needed.  Continuing service (aftercare or post-
discharge service) is almost always helpful and necessary.  Recovery-support services offered by 
specially trained peer support professionals should be offered to those in recovery. 
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V. Community-Based Treatment 
Recommendation with Potential Fiscal Impact:  The Council recommends expanding 
community-based services for substance use disorder treatment and recovery support. 
Continuing treatment, such as post-discharge service, is almost always helpful and 
necessary for individuals recovering from SUDs.  Treatment and recovery-support services 
offered by specially trained professionals should be readily available.  All treatment programs, 
public and private, in South Carolina would benefit from expansion of peer-support training and 
financial support for recovery services beyond the minimum effective dose of inpatient or 
outpatient treatment. 
Treatment services should also include screening for co-occurring disorders such as 
depression and anxiety.  These conditions are linked very closely with current alcohol and other 
drug use and the subsequent primary withdrawal and secondary (post-withdrawal) period.  
Treating these conditions simultaneously results in positive outcomes for patients while 
conserving resources. 
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PRIORITY AREA:  EDUCATION AND ADVOCACY 
As with any public health epidemic, education will be a very important component in 
turning the tide of prescription drug abuse in our state.  Many South Carolinians may be unaware 
of the astounding statistics associated with prescription drug abuse, both nationally and in our 
state.  Two groups must be educated on the dangers of this epidemic and their role in preventing 
it:  1) present and future prescribers and dispensers of controlled substances; and 2) the general 
public. 
In 2011, the Office of National Drug Control Policy published a national strategy that 
outlines specific tactics to reduce by 15% the non-medical use of prescription drugs among 
people 12 years of age and older, and included in those tactics is the education of patients, 
prescribers, and the general public.
34
  In all of the successful state plans reviewed by the Council, 
education and advocacy proved to be a very important component.  Utah developed a campaign 
titled ―Use Only as Directed,‖35 and Kentucky embarked on a crusade to ―unsell drugs‖ to the 
public, particularly their youth.
36
  As a part of South Carolina’s Plan, the Council recommends a 
similar campaign to educate the groups identified above. 
The Council’s Education and Advocacy recommendations for prescribers are listed in the 
Prescribers section above.  
I. Dispensers 
Recommendation:  The Council recommends mandatory continuing education for pharmacists 
regarding SCRIPTS and general education on the problem itself.  Further, the Council 
recommends reaching out to the pharmacy schools to increase course offerings related to the 
subject. 
Pharmacists are partners in ensuring that all prescriptions filled for controlled substances 
are for legitimate medical purposes.  In fact, pharmacists are the last line of defense prior to the 
controlled substance reaching the hands of the patient.  Like prescribers, dispensers should 
utilize SCRIPTS to ensure that they are properly filling prescriptions.  Similar to prescribers, 
dispensers have low utilization rates of this system, and do not receive much formal education 
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regarding the system. The Council recommends partnering with the pharmacy schools in the 
state, Medical University of South Carolina, Presbyterian College, University of South Carolina 
School of Pharmacy, and South University to increase course offerings related to this topic.   
II. General Public 
Targeting healthcare professionals alone is not enough.  Seventy percent of 12
th
-graders 
reported that they obtained prescription narcotics for nonmedical use from a friend or relative, 
not directly from a healthcare provider.
37
  And, according to NIDA, public misperception about 
the safety of prescription drugs is one of the key factors driving the high prevalence of 
prescription drug abuse.
38
  Given this, the Council must also focus its efforts on a public 
education campaign that warns about the dangers of prescription-drug misuse and easy access to 
them in the home. 
Parents and educators might not realize that 1 in 12 high school seniors report 
nonmedical use of Vicodin, and 1 in 20 report abuse of OxyContin.
39
  And more alarming, 
parents may be unaware of the statistic that 70% of these 12
th
-graders report obtaining these 
drugs from a friend or relative.
40
 
Further, many South Carolinians, adults and children alike, may be misled into believing 
that because a healthcare professional prescribes certain drugs, they are safer than illicit drugs.  
This is false.  In fact, prescription drugs act directly or indirectly on the same brain systems 
affected by illicit drugs.
41
  And, although prescription drugs can be powerful allies, they also 
pose serious health risks related to their abuse. 
Existing and future community coalitions will be a key component to any public 
education campaign.  South Carolina currently has 11 Drug Free Communities Grant Program 
sites, which are funded by the federal Office of National Drug Control Policy and the Substance 
Abuse and Mental Health Services Administration.  These coalitions have participated in the 
U.S. Drug Enforcement Administration’s ―take-back days‖ in the past and may also be working 
on other prevention strategies to address prescription drug abuse among young people.  The 11 
coalitions are: 
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1. York County All On Board Coalition 
2. Coalition on Underage Drinking (Newberry) 
3. The Project CARE Coalition (Richland School District Two) 
4. The Berkeley County Prevention Board 
5. Chesterfield County Coordinating Council 
6. Richland One Community Coalition 
7. Florence County Coalition for Alcohol and Other Drug Abuse Prevention 
8. Steppin’ It Up Coalition (Pickens) 
9. Community Alcohol and Drug Impact Coalition (Spartanburg) 
10. MCIAC Drug Free Marlboro Coalition 
11. Rise Above It (West Columbia)42 
Other coalitions may exist in communities that the Council is unaware of, and it will be 
important for the Council to work with the above coalitions, other existing coalitions, and assist 
communities in beginning new coalitions. 
Recommendation with Potential Fiscal Impact:  The Council recommends engaging a 
marketing firm or state or university employees to develop a marketing campaign and identify 
the target audience.  The Council recommends that the campaign’s message include, but not be 
limited to, the following three components: 
 dangers of prescription drug abuse; 
 proper disposal of prescription drugs, including available disposal sites; and 
 use of SC 211 information helpline for opioid addiction. 
Recommendation:  Once the plan is developed, the Council recommends reaching out to the 
existing community coalitions, the South Carolina Department of Education, and professional 
associations to distribute marketing materials through schools, hospitals, physician and dental 
offices, and pharmacies.  Further, the Council recommends reaching out to local communities 
without an existing coalition to assist them in building one. 
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PRIORITY AREA:  DATA AND ANALYSIS 
The Council formed a Data Committee, comprised of representatives from multiple state 
agencies, to identify how the State’s management of data can assist with the design and 
measurement of success of a comprehensive prescription drug abuse prevention plan.  The Data 
Committee reviewed the benchmarks established by the Council and assessed three factors for 
each of the nine policy tracks (i.e., Pharmacy, Prescription Drug Monitoring, Treatment, Law 
Enforcement, Third-Party Payers, Education and Advocacy, County/Community Initiatives, 
Unintended Consequences, and Prescribers).  First, the Data Committee considered whether the 
proposed benchmarks are currently measured.  If so, the Data Committee further inquired about 
how the data is currently collected and where it is stored.  If not currently measured, the Data 
Committee considered how the proposed measurement can be implemented.  Second, the Data 
Committee identified potential gaps in either data currently collected or proposed for collection.  
Finally, the Data Committee identified action steps necessary to improve either the current or 
proposed statistics, including required legislative action.  These are the benchmarks by which the 
Plan’s impact will be measured. 
The Data Committee’s analysis is set forth in a spreadsheet as Appendix B. 
I. Memorandum of Understanding on Information Sharing 
Recommendation:  The Council recommends that the Department of Health and Environmental 
Control (DHEC) and the Department of Health and Human Services (DHHS) work on a 
Memorandum of Understanding to facilitate information sharing between SCRIPTS and existing 
comprehensive databases. 
SCRIPTS is a highly valuable, but underused, repository of raw data that may be 
analyzed for multiple purposes.  However, SCRIPTS data is only one piece of the puzzle.  South 
Carolina state agencies are utilizing other databases to collect data relevant to the prescription 
drug abuse epidemic. 
For example, the South Carolina Health and Human Services Data Warehouse, created 
pursuant to S.C. Code Ann. 44-136-20, et. seq., collects data from over 17 different state 
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agencies.  Segments of that data may relate to prescription drug use and abuse, mental health 
diagnoses, hospitalizations, and other treatment interventions and third-party payer information 
from the Medicaid and Public Employee Benefit Authority databases.  Section 44-6-170 created 
the Data Oversight Council to make recommendations to the Joint Legislative Health Care 
Planning and Oversight Committee regarding the collection and release of healthcare-related 
data collected from healthcare providers or insurers.  All the compiled data is stored by the 
newly formed Revenue and Fiscal Affairs (RFA) Office, formerly known as the Office of 
Research and Statistics. 
The current challenge is that the data compiled in the databases supported by DHHS and 
housed by RFA is not linked to SCRIPTS.  Accordingly, the Data Committee recommends that 
DHEC and DHHS work together to craft and execute a Memorandum of Understanding or other 
appropriate framework to facilitate the exchange of data stored in the respective databases while 
preserving the appropriate level of confidentiality and security. 
II. Tracking Prescription Drug-Related Convictions 
Recommendation with Potential Fiscal Impact:  The Council recommends exploring with the 
South Carolina Court Administration and Solicitor’s Association the possibility of creating a 
database for tracking all prescription drug-related convictions. 
South Carolina currently has a system for tracking arrests, although even that does not 
currently segregate prescription drug offenses from illicit drug offenses or delineate which 
substances are involved.  While there is a need to enhance the way South Carolina documents its 
arrests, there is an even greater need to develop a comprehensive database for capturing data 
regarding the prosecution of prescription drug-related offenses. 
Solicitor’s Offices around the state track the work conducted within each respective 
office.  Each Solicitor’s Office can track the arrest history, prosecutions, and specific criminal 
codes.  However, there is no comprehensive database where the individual solicitors’ 
information is compiled. 
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The Data Committee recommends exploration of the possibility of developing a 
comprehensive database for tracking prescription drug-related offenses so that the existing 
challenge can be properly identified and future progress measured. 
III. Data From Adult Drug Courts 
Recommendation:  The Council recommends identifying counties with adult drug court and 
seeking information from those counties regarding currently collected data. 
Adult drug courts are held in some, but not all, counties and may provide data regarding 
county-specific prescription drug issues.  Data from the existing drug court programs can 
facilitate the identification and enrichment of alternatives to imprisonment for individuals who 
may need help more than incarceration.  A further recommendation may include the 
development of a repository for the existing adult drug courts programs’ data. 
IV. Medication-Assisted Treatment 
Recommendation:  The Council recommends identifying medication-assisted treatment (MAT) 
options for individuals battling prescription drug addiction and tracking the use of MAT in South 
Carolina. 
Other states have documented an increase in the number of prescriptions utilized in MAT 
programs, including but not limited to buprenorphine, naloxone, and methadone, as efforts to 
deter prescription drug abuse.  There is anticipation that South Carolina will follow this trend.  
Accordingly, it will be useful to begin tracking this information to determine whether there is an 
increase in the utilization of MAT-related prescriptions.  SCRIPTS can provide data regarding 
the number of prescriptions for these substances, excluding methadone from methadone clinics.  
However, that data will not provide a comprehensive analysis of the utilization of MAT 
programs. 
Additional input is necessary from the treatment community regarding suggestions for 
appropriate metrics and data sources to accurately gauge how many South Carolinians pursue 
MAT options. 
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V. Revision of ReLAES Database 
Recommendation:  The Council recommends that the Department of Labor, Licensing and 
Regulation (LLR) revise its ReLAES database to designate disciplinary matters with a 
searchable identifier for prescription drug misuse/abuse/addiction cases. 
ReLAES, LLR’s internal database, does not currently specify the offenses for which 
licensees are disciplined relating to prescription drug issues.  For example, if a physician is 
disciplined for diversion of a controlled substance or diagnosed with a prescription drug 
addiction, the system is not currently programmed to produce a report containing that 
information.  ReLAES can be modified to add searchable fields for prescription drug-related 
actions. 
VI. “Special Circumstances” Field for SLED 
Recommendation:  The Council recommends that the South Carolina Law Enforcement 
Division (SLED) add a “special circumstances” field to designate prescription drug matters. 
South Carolina’s Incident Reporting System is submitted to the Federal Bureau of 
Investigation (FBI) pursuant to FBI regulations.  The information entered falls into general 
categories and currently does not specify offenses related to prescription drugs.  SLED can 
customize the data entry to include a field called ―special circumstances,‖ whereby SLED can 
assign a one-letter code to represent prescription drug offenses.  This would allow SLED to 
generate a report that accurately reflects the number and types of prescription drug cases 
investigated.  A report is generated from the database and published annually.  The addition of a 
―special circumstances‖ field for prescription drug cases will require training of all law 
enforcement agencies that enter data into the system.  Local agencies may not utilize the field 
uniformly, so comprehensive training will be necessary to enhance the reliability of the data.  
The Data Committee recommends the designation of separate unique identifiers for opioids and 
benzodiazepines. 
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VII. Development of Comprehensive Database for Prescription Drug-Related Deaths 
Recommendation with Potential Fiscal Impact:  The Council recommends that coroners 
uniformly report causes and manner of death so that a comprehensive reporting system exists to 
track deaths associated with prescription drug abuse and/or overdose.  To rectify this data error, 
the Council recommends that DHEC add a data field on the electronic death certificate that 
requires a coroner to specify the type of implicated drugs, prescription or illicit, in cases of 
overdose deaths. 
Recommendation:  Further, the Council recommends expanding training for coroners and 
medical examiners.  In South Carolina, coroners must annually complete 16 hours of continuing 
education, most of which is offered by the South Carolina Coroner’s Association.  Currently, 
coroners are offered a course regarding best practices in identifying drug-related deaths.  The 
Council recommends that DHEC work with the Coroner’s Association to add a component to 
this course regarding the proper reporting of these deaths. 
One important benchmark in establishing the baseline data and measuring the success of 
the Council’s efforts going forward is the annual number of deaths attributable to prescription 
drug overdose/abuse (adult and youthful populations) in South Carolina.  By statute, each of the 
46 county coroners must report all suspected drug overdose deaths to DHEC.  The Council has 
learned that this metric may not be consistently measured and reported throughout the state.  In 
reporting, some coroners specify whether the implicated drug is a prescription or illicit drug, 
others do not, and others do so inconsistently.  Thus, the number of prescription drug overdose 
deaths in South Carolina is likely understated.  An existing database, Web Death, may be 
maximized to enhance greater uniform reporting.  Additional training and allocation of resources 
may be necessary to assist with the push toward uniformity. 
VIII. Inclusion of Additional Metrics 
Recommendation:  The Council recommends that additional metrics be added to the current 
benchmarks as the Plan is implemented and revised. 
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Additional benchmarks would include the following: 
 the number of valid prescriptions held by a decedent at the time of death in cases 
where prescription drug use is a possible contributing factor to the death; 
 the proportion of patients with X MED (to be determined by the Board of Medical 
Examiners) who have had at least one (1) SCRIPTS inquiry; 
 the number or percentage of patients who are prescribed both opioids and 
benzodiazepines; 
 the proportion of South Carolinians who have filled prescriptions for quantities in 
excess of X, to be determined by the Board of Medical Examiners; and 
 the number of administrations of Naloxone by first responders. 
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PRESCRIPTION DRUG ABUSE PREVENTION COUNCIL 
RECOMMENDATION SUMMARY 
PRIORITY AREA:  PRESCRIBERS 
Recommendation:  The Council recommends that the Medical Board, the South Carolina 
Department of Health and Environmental Control, and other stakeholders work together to 
create a suggested list of topics for the education providers to include in the mandated training. 
Recommendation:  The Council recommends extending the education mandate contained in Act 
244 to dentists, physician assistants, and advanced practice nurses with prescriptive authority. 
Recommendation:  The Council recommends working with schools to increase course offerings 
related to this topic or make it a mandatory part of the curriculum. 
Recommendation:  The Council strongly encourages all prescribers to be familiar with the 
Revised Pain Management Guidelines contained in Appendix A to this Plan and to conform their 
prescribing practice to these Revised Guidelines. 
Recommendation:  The Council recommends that prescribers be knowledgeable about all state 
and federal laws and regulations regarding controlled substances. 
Recommendation:  The Council recommends that registration and utilization of SCRIPTS be 
considered mandatory for prescribers to provide safe, adequate pain management. 
Recommendation:  The Council recommends that prescribers who prescribe chronic opioid 
therapy be familiar with treatment options for opioid addiction, including those available in 
licensed opioid treatment programs and those offered by an appropriately credentialed and 
experienced physician through office-based opioid treatment, so as to make appropriate 
referrals when needed. 
Recommendation:  The Council recommends prescribers treating patients with controlled 
substances consider prescribing Naloxone when clinically indicated. 
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Recommendation:  The Council strongly encourages the Boards of Medical Examiners, 
Dentistry, and Nursing to continue to update the Revised Pain Management Guidelines as 
lessons are learned and when data suggests that changes are needed. 
Recommendation:  SCRIPTS must be as user friendly as possible to facilitate easy use.  
Recommendation:  The Bureau of Drug Control (BDC) and Boards have a shared interest in 
correcting improper prescribing behaviors, through education when possible and enforcement 
when necessary. Upon establishment of criteria by the Board of Medical Examiners, which may 
include, but are not limited to, a daily MED threshold and prescription volume by prescriber, 
SCRIPTS shall generate reports by which outlier prescribers will be identified for further review 
by the BDC and, if necessary, referral to LLR for initiation of the complaint process. 
Recommendation:  Based on the Revised Guidelines, the Council recognizes that patients 
requiring more than 80 MED present an increased risk of death from respiratory depression. 
Accordingly, the Council recommends that, when capable, SCRIPTS offer an MED calculator 
that can generate an alert for each patient whose record is accessed and for which the MED 
exceeds 80 MED. The MED calculator and alert function will provide an additional tool for the 
prescriber to utilize when assessing a patient’s prescriptive needs. This threshold is not a 
substitute for a prescriber’s clinical judgment, but merely one factor for consideration in the 
prescribing process. 
Recommendation:  The BDC shall utilize the full analytical capabilities of SCRIPTS to identify 
prescribers engaged in questionable prescribing activities. 
Recommendation:  Information shared between LLR and DHEC may be used to assist the BDC 
in promptly identifying a prescriber’s area of specialization, if applicable, when investigating a 
licensee’s prescribing behavior. 
Recommendation with Potential Fiscal Impact:  The Council and the Boards support the 
compilation and distribution of report cards to all South Carolina licensed prescribers so that 
each prescriber can see how his or her prescribing patterns compare to other prescribers 
practicing in the same or similar clinical setting.  
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Recommendation:  Prescribers engaged in conduct not rising to the level of criminal activity, 
but who may benefit from additional education or counseling regarding appropriate prescribing, 
shall be identified by the BDC and provided an educational intervention.  
Recommendation:  Prescribers identified by the BDC engaged in conduct rising to the level of 
criminal activity, shall be subjected to the standard process of investigation by the BDC, arrest, 
where appropriate, and referral to LLR for investigation of unprofessional conduct. 
Recommendation:  The Council recommends that the Boards identify licensees with expertise in 
ethical prescribing to serve as hearing officers or hearing panel members in any disciplinary 
cases arising from prescribing behavior. These designated individuals shall hear and review 
disciplinary matters and make recommendations to the applicable regulatory board for final 
action as set forth in each profession’s Practice Act and regulations. These individuals shall not 
be the same licensees identified to serve as voluntary mentors. 
PRIORITY AREA:  THE SOUTH CAROLINA PRESCRIPTION MONITORING 
PROGRAM 
Recommendation:  The Council recommends that prescriber registration and enrollment in 
SCRIPTS become required and recommends that each patient’s prescription history is reviewed 
in certain circumstances prior to the prescription of controlled substances. 
Recommendation with Potential Fiscal Impact:  The Council recommends that DHEC 
proceed to acquire analytic services and/or products to work with SCRIPTS data, expanding the 
capacity to develop predictive models and to detect anomalies in prescriber patterns and patient 
prescription behaviors.  The Council further recommends that DHEC send letters notifying 
prescribers of suspicious behavior identified by the analytics. 
Recommendation with Potential Fiscal Impact:  The Council recommends that DHEC 
coordinate real-time hosting of data from other state agencies to include, but not be limited to, 
the South Carolina Department of Alcohol and Other Drug Abuse Services; South Carolina 
Department of Mental Health; South Carolina Department of Juvenile Justice; South Carolina 
Department of Social Services (DSS); South Carolina Department of Health and Human 
Services (DHHS); South Carolina Attorney General’s Office; South Carolina Department of 
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Probation, Parole, and Pardon Services; South Carolina Department of Corrections; South 
Carolina Prosecution Commission; and the South Carolina Law Enforcement Division. 
Recommendation with Potential Fiscal Impact:  The Council recommends that DHEC and the 
Revenue and Fiscal Affairs Office collaborate and create capacity for information sharing 
between SCRIPTS and South Carolina Health Information Exchange (SCHIEx). 
Recommendation with Potential Fiscal Impact:  The Council recommends that DHEC work 
with prescribers and healthcare providers to integrate SCRIPTS data into electronic health 
records, so that access to patients’ controlled substance records does not interrupt prescriber 
workflow. 
Recommendation:  The Council recommends that Governor Haley request by letter the States 
of North Carolina and Georgia enroll in the National Association of Boards of Pharmacy’s 
Prescription Monitoring Program Interconnect hub to afford enhanced regional monitoring.  
Recommendation:  The Council recommends that the BDC continue and expand initiatives to 
coordinate education and awareness campaigns for SCRIPTS, to include outreach to more 
stakeholders such as provider associations, licensing boards, and investigative agencies. 
PRIORITY AREA:  PHARMACY 
Recommendation with Potential Fiscal Impact:  The Council recommends expanding 
prescription drug take-back programs across the state. 
Recommendation:  The Council recommends regulating non-resident entities dispensing 
controlled substances into the state. 
Recommendation:  The Council recommends increasing the number of pharmacists registered 
to use SCRIPTS. 
Recommendation:  The Council recommends that the professional boards and associations 
work with practitioners, pharmacies, and software vendors to encourage electronic transmission 
for all classes of controlled substance prescriptions. 
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PRIORITY AREA:  THIRD-PARTY PAYERS 
Recommendation:  The Council recommends that third-party payers adjust payer policies in 
accordance with the Revised Pain Management Guidelines outlined in the Prescribers section 
above and attached as Appendix A. 
Recommendation:  The Council recommends that third-party payers continue to adopt and 
revise interventions to address controlled substance misuse and abuse by beneficiaries, including 
participation in multi-agency data sharing with the Bureau of Drug Control Prescription 
Monitoring Program. 
Recommendation:  The Council recommends that third-party payers adapt pharmacy benefits 
packages to encourage appropriate use of opioids. 
Recommendation with Potential Fiscal Impact:  The Council recommends healthcare payer 
coverage for screening and treatment for substance use disorders. 
PRIORITY AREA:  LAW ENFORCEMENT 
Recommendation with Potential Fiscal Impact:  The Council recommends expanding law 
enforcement sponsorship of prescription drug take-back programs. 
Recommendation:  The Council recommends increasing awareness and education of law 
enforcement to identify potential misuse of prescription drugs. 
Recommendation:  The Council recommends increasing law enforcement participation in 
community-based prevention programs. 
Recommendation with Potential Fiscal Impact:  The Council recommends continuing and 
expanding investigation and prosecution efforts specific to prescription drug diversion. 
Recommendation:  The Council recommends that law enforcement agencies and prosecutors 
work together to propose to the Legislature defined statutory amounts of opiods and other 
Schedule I through V controlled substances to qualify for the charges of Possession, Possession 
with the Intent to Distribute (PWID), and Trafficking. 
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PRIORITY AREA:  TREATMENT 
Recommendation with Potential Fiscal Impact:  The Council recommends expanding 
medication-assisted treatment (MAT) services for prescription opioid dependency and addiction, 
and integrating MAT and medication management services with recovery support services, and 
therapeutic interventions for substance use disorders, so that both are available to all 
individuals as conditions indicate. 
Recommendation:  The Council recommends coordinating substance use disorder treatment 
services with co-occurring, clinically substantiated pain-management needs. 
Recommendation:  The Council recommends establishing a protocol for primary care 
practitioners to refer cases of prescription drug addiction to treatment, and establishing a 
protocol for treatment providers to refer and navigate individuals to primary care. 
Recommendation:  The Council recommends providing family education and services, inclusive 
of substance use disorder treatment and recovery services. 
Recommendation with Potential Fiscal Impact:  The Council recommends expanding 
community-based services for substance use disorder treatment and recovery support. 
PRIORITY AREA:  EDUCATION AND ADVOCACY 
Recommendation:  The Council recommends mandatory continuing education for pharmacists 
regarding SCRIPTS and general education on the problem itself.  Further, the Council 
recommends reaching out to the pharmacy schools to increase course offerings related to the 
subject. 
Recommendation with Potential Fiscal Impact:  The Council recommends engaging a 
marketing firm or state or university employees to develop a marketing campaign and identify 
the target audience.  The Council recommends that the campaign’s message include, but not be 
limited to, the following three components: 
 dangers of prescription drug abuse; 
 proper disposal of prescription drugs, including available disposal sites; and 
 use of SC 211 information helpline for opioid addiction. 
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Recommendation:  Once the plan is developed, the Council recommends reaching out to the 
existing community coalitions, the South Carolina Department of Education, and professional 
associations to distribute marketing materials through schools, hospitals, physician and dental 
offices, and pharmacies.  Further, the Council recommends reaching out to local communities 
without an existing coalition to assist them in building one. 
PRIORITY AREA:  DATA AND ANALYSIS 
Recommendation:  The Council recommends that the Department of Health and Environmental 
Control and the Department of Health and Human Services (DHHS) work on a Memorandum of 
Understanding to facilitate information sharing between SCRIPTS and existing comprehensive 
databases. 
Recommendation with Potential Fiscal Impact:  The Council recommends exploring with the 
South Carolina Court Administration and Solicitor’s Association the possibility of creating a 
database for tracking all prescription drug-related convictions. 
Recommendation:  The Council recommends identifying counties with adult drug courts and 
seeking information from those counties regarding currently collected data. 
Recommendation:  The Council recommends identifying medication-assisted treatment (MAT) 
options for individuals battling prescription drug addiction and tracking the use of MAT in South 
Carolina. 
Recommendation:  The Council recommends that the Department of Labor, Licensing and 
Regulation (LLR) revise its ReLAES database to designate disciplinary matters with a 
searchable identifier for prescription drug misuse/abuse/addiction cases. 
Recommendation:  The Council recommends that the South Carolina Law Enforcement 
Division (SLED) add a “special circumstances” field to designate prescription drug matters. 
Recommendation with Potential Fiscal Impact:  The Council recommends that coroners 
uniformly report causes and manner of death so that a comprehensive reporting system exists to 
track deaths associated with prescription drug abuse and/or overdose.  To rectify this data error, 
the Council recommends that DHEC add a data field on the electronic death certificate that 
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requires a coroner to specify the type of implicated drugs, prescription or illicit, in cases of 
overdose deaths. 
Recommendation:  Further, the Council recommends expanding training for coroners and 
medical examiners.  In South Carolina, coroners must annually complete 16 hours of continuing 
education, most of which is offered by the South Carolina Coroner’s Association.  Currently, 
coroners are offered a course regarding best practices in identifying drug-related deaths.  The 
Council recommends that DHEC work with the Coroner’s Association to add a component to 
this course regarding the proper reporting of these deaths. 
Recommendation:  The Council recommends that additional metrics be added to the current 
benchmarks as the Plan is implemented and revised. 
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SUMMARY OF RECOMMENDATIONS REQUIRING 
PROPOSED LEGISLATIVE CHANGES 
Recommendation:  The Council recommends extending the education mandate contained in Act 
244 to dentists, physician assistants, and advanced practice nurses with prescriptive authority. 
Recommendation:  The Council recommends that prescriber registration and enrollment in 
SCRIPTS become required and recommends that each patient’s prescription history is reviewed 
in certain circumstances prior to the prescription of controlled substances. 
Recommendation with Potential Fiscal Impact:  The Council recommends that DHEC 
proceed to acquire analytic services and/or products to work with SCRIPTS data, expanding the 
capacity to develop predictive models and to detect anomalies in prescriber patterns and patient 
prescription behaviors.  The Council further recommends that DHEC send letters notifying 
prescribers of suspicious behavior identified by the analytics. 
Recommendation:  The Council recommends that law enforcement agencies and prosecutors 
work together to propose to the Legislature defined statutory amounts of opioids and other 
Schedule I through V controlled substances to qualify for the charges of Possession, Possession 
with the Intent to Distribute (PWID), and Trafficking. 
Recommendation:  The Council recommends mandatory continuing education for pharmacists 
regarding SCRIPTS and general education on the problem itself.  Further, the Council 
recommends reaching out to the pharmacy schools to increase course offerings related to the 
subject. 
Recommendation:  A further recommendation by the Data Committee is that all public schools 
participate in surveys of nonmedical use of prescription and illicit drugs. 
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APPENDIX C 
 
JOINT REVISED PAIN MANAGEMENT GUIDELINES 
APPROVED BY 
THE SOUTH CAROLINA BOARDS OF MEDICAL EXAMINERS,  
DENTISTRY AND NURSING 
 
November 2014 
 
The South Carolina Board of Medical Examiners (Medical Board) published Pain 
Management Guidelines (Guidelines) to assist physicians in safely prescribing controlled 
substances in July of 2009.  Increasing opioid misuse and abuse, recent research and clinical 
studies now require the revision of those Guidelines to provide adequate information to ensure 
safe and appropriate treatment of pain.  Additionally, the Medical Board recognizes that 
physicians, dentists, physician assistants, and advance practice registered nurses with 
prescriptive authority should all adhere to uniform prescriptive guidelines.  Accordingly, the 
South Carolina Board of Dentistry (Dental Board) and South Carolina Board of Nursing 
(Nursing Board) have joined the Medical Board in approving these Joint Revised Pain 
Management Guidelines (Revised Guidelines).
1
  These Revised Guidelines strongly consider the 
evidence that the health risks of high dose opioid use have increased, while the evidence for 
benefits remains controversial and insufficient.  In the Revised Guidelines, the Dental Board, 
Medical Board and Nursing Board (the Boards), adopt language, in part, similar to that used by 
the North Carolina Medical Board in an effort to create a uniform policy along our common 
border. 
These Revised Guidelines are designed to communicate to licensees that the Boards view 
pain management as an important area of patient care integral to the practice of medicine; that 
opioid analgesics may be necessary for the relief of certain pain conditions; and that prescribers 
will not be sanctioned solely for prescribing opioid analgesics of the dose prescribed for 
legitimate medical purposes.  Further, the Revised Guidelines are intended to alleviate prescriber 
uncertainty and to encourage patient-centered care.  These Revised Guidelines are intended to 
reinforce the exercise of sound clinical judgment while discouraging prescriptive behaviors that 
may lead to misuse or abuse of controlled substances, including opioids. 
These Revised Guidelines serve to protect South Carolinians’ access to pain care while 
combating prescription drug misuse, abuse, diversion and addiction.  Prescribers must be held to 
a safe and best clinical practice.  The Federal Controlled Substances Act defines a ―lawful 
prescription‖ as one that is issued for a legitimate medical purpose by a practitioner acting in the 
usual course of professional practice.  The use of opioids for other than legitimate medical 
purposes poses a threat to the individual and to the public health, thus imposing on prescribers a 
                                                     
1
 
1
 The Board of Medical Examiners endorsed the Revised Guidelines on November 3, 2014.  The Board of Dentistry 
endorsed the Revised Guidelines on November 13, 2014.  The Board of Nursing endorsed the Revised Guidelines 
on November 20, 2014. 
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responsibility to minimize potential for misuse, abuse and diversion of opioids and all other 
controlled substances. 
Prescribers must recognize that inappropriate prescribing of controlled substances may 
contribute to drug misuse and diversion by individuals who seek opioids for other than legitimate 
medical purposes.  Inappropriate treatment can result from a mistaken belief on the part of 
patients and their prescribers that complete eradication of pain is an attainable goal that can be 
achieved without disabling adverse effects.  Accordingly, the Boards urge prescribers to 
incorporate safeguards into their practices to minimize the risks of misuse, abuse and diversion 
of opioid analgesics and other controlled substances.  The consensus is that utilization of 
SCRIPTS prior to prescribing opiates is the best safeguard against these risks and the best 
practice for prescribers. 
Preamble 
The Boards recognize that principles of quality medical practice dictate that South 
Carolinians have access to appropriate and effective pain relief. 
The appropriate application of up-to-date knowledge and treatment modalities can serve 
to improve the quality of life for those patients who suffer from pain, as well as reduce the 
morbidity and costs associated with untreated or inappropriately treated pain.  These Revised 
Guidelines apply to the treatment of both acute and chronic pain with opioid analgesics, as well 
as clinical strategies to improve appropriate, safe prescribing of controlled substances and 
treatments.  The use of opiates in end of life and palliative care may present unique benefits and 
risks not fully addressed herein.  However, concepts presented will be relevant and generally 
applicable to the use of opiates for end of life and palliative care. 
Persistent, intractable pain, like all chronic illnesses, is managed optimally with a bio-
psychosocial model and not with opio-centric practices of the past.  A continuum of care in 
choosing possible opioid and nonopioid alternatives is preferred, depending on the clinical 
situation and prescriber discretion as to safe and appropriate treatment. 
Below, the Boards issue guidance on the Treatment of Pain, including chronic and acute 
pain and pain in the emergency department; the Inappropriate Treatment of Pain; Actions 
Outside the Scope of Appropriate Pain Management; and other Special Considerations. 
I. GENERAL PRINCIPLES ON STANDARD OF CARE 
It will be considered the standard of care to assess and evaluate the current status of pain 
treatment prior to initiating new treatment or adjusting current treatment.  The registration and 
utilization of SC PMP/SCRIPTS program (SCRIPTS), which provides both a current and 
historical survey of narcotic, sedative and controlled substance use, is considered mandatory for 
prescribers to provide safe, adequate pain treatment.  Drug screening is strongly recommended, 
when indicated.  Prescribers are responsible for ordering, prescribing, dispensing or 
administering controlled substances, including opioid analgesics, for a legitimate medical 
purpose and in the course of professional practice.  The Boards regulating prescribers will 
consider prescribing, ordering, dispensing or administering controlled substances for pain to be 
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for a legitimate medical purpose if based upon documented, sound clinical judgment.  All such 
prescribing must be based on clear documentation of unrelieved pain.  To be within the usual 
course of professional practice, a practitioner-patient relationship must exist and the prescription 
should be based on a diagnosis and documentation of unrelieved pain.  Compliance with 
applicable state and federal law is required. 
The Boards recognize that controlled substances, including opioid analgesics, may be 
essential in the treatment of acute pain due to trauma or surgery and chronic pain, whether due to 
cancerous or noncancerous origins.  The Boards will refer to current clinical practice guidelines 
and expert review in the investigation and review of cases involving management of pain.  The 
medical management of pain should consider current clinical knowledge and scientific research 
and the use of pharmacologic and nonpharmacologic modalities according to the judgment of the 
prescriber. 
Pain should be assessed and treated promptly.  The selection of therapeutic modalities, 
including the quantity and frequency of medication doses, should be adjusted according to the 
nature of the pain, the patient’s response to treatment, and the patient’s risk level relative to the 
use of medications with abuse potential.  Prescribers should recognize that tolerance and physical 
dependence are normal consequences of sustained use of opioid analgesics and are not the same 
as addiction. 
II. GUIDELINES FOR THE TREATMENT OF PAIN 
These Revised Guidelines are meant to help prescribers evaluate and manage pain 
appropriately, prescribe opiates responsibly, and prevent opioid diversion and abuse.  
Incorporation of these best practices will help prescribers mitigate some of the burden that pain 
and its attendant opiate use place on patients, prescribers, medical institutions and society.  The 
Boards strongly recommend the following as a reference for behavior when using opiates to treat 
pain. 
A. TREATMENT OF CHRONIC PAIN 
Prescribers who treat patients with chronic pain are strongly encouraged to be 
knowledgeable about addiction, including behaviors that indicate addiction and 
circumstances under which it is appropriate to refer a patient for addiction evaluation and 
treatment.  Essential elements of appropriate pain management include:  evaluation of the 
patient, consideration of alternative treatments, development of a treatment plan and 
goals individualized to the patient’s needs, informed consent and a treatment agreement, 
initiation of treatment on a trial basis, periodic review and possible drug testing, 
consideration of drug diversion, possible consultation and referrals, thoughtful 
discontinuation of treatment, and appropriate documentation of medical records. 
Evaluation of the Patient 
A medical history and physical examination must be obtained, evaluated, and 
documented in the medical record. The medical record should document the nature and 
intensity of the pain, current and past treatments for pain, underlying or coexisting 
diseases or conditions, the effect of the pain on physical and psychological function and 
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history of substance abuse.  The medical record also should document the presence of 
one or more recognized medical indications for the use of a controlled substance. 
SCRIPTS utilization should be part of every patient’s initial evaluation and 
subsequent monitoring program and is considered the standard of care.  Failure to utilize 
SCRIPTS to assess risk of opiate/sedative prescribing may be considered misconduct by 
the responsible regulatory board, depending upon the clinical situation.  Prescribers 
should register with SCRIPTS and become familiar with analyzing and using SCRIPTS 
data. Information from the SCRIPTS should be used to help confirm each patient’s 
compliance with treatment plans and opiate medication agreements.  Relevant 
information from the SCRIPTS should become part of the patient’s medical record. 
A toxicology screen, such as a urine drug screen, is a useful tool in the assessment 
of risks associated with prescribing higher dose opioids and should be utilized prior to 
prescribing opioids for treatment of chronic pain.  It may reveal the use of controlled 
medications other than those prescribed, such as opioids or benzodiazepines, or the use of 
illicit drugs. 
Evaluation and risk stratification assume even greater importance when dealing 
with a patient who is taking opioids prescribed by another prescriber.  The prescriber’s 
decision to prescribe opioid analgesics should reflect the totality of the information 
collected, the prescriber’s own knowledge and comfort level in prescribing, and the 
resources available in the community for patient support. 
Consideration of Alternative Treatments to Opioid Therapy 
Consideration and utilization of a multimodal approach to patient care is essential.  
A prescriber treating a patient seeking care for pain should have knowledge of all 
available treatment options, including, but not limited to:  physical therapy; non-opioid 
medications; injections; surgical options; cognitive and behavioral methods; 
rehabilitation approaches; and complementary treatments.  These should be explored and 
documented as part of a routine evaluation.  Early treatment with non-pharmacologic 
interventions including physical therapy, exercise, and cognitive behavioral techniques, 
should be employed whenever possible.  First line pharmacotherapy should be the 
appropriate use of non-opioid analgesics, including over the counter medication, non-
steroidal anti-inflammatory drugs, and acetaminophen.  Other treatment modalities, 
including minor intervention such as anesthetic and steroid joint injections, cutaneous 
stimulation, topical anesthetics, and local therapies employing heat, massage, and 
manipulations, should be considered before using opiates. 
If the prescriber determines that opioid therapy is the best course of treatment 
after review and/or utilization of alternative treatments, the prescriber should minimize 
the risks of respiratory depression, addiction, and diversion.  When opioids are identified 
as the best treatment option for complex or high-risk patients, specialists in psychology, 
psychiatry, and addiction management should be consulted, if possible. 
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Development of a Treatment Plan and Goals 
The decision to initiate opioid therapy for treatment of chronic pain should be the 
prescriber and patient’s joint decision.  This decision may extend to another person 
responsible for the patient’s care (Caretaker).  Once the joint decision to prescribe is 
made, a treatment plan and goals should be established as early as possible in the 
treatment process and revisited regularly.  The prescriber should discuss the risks and 
benefits of the treatment plan, including any proposed use of opioid analgesics, with the 
patient and any Caretaker or other person(s) designated by the patient.  If opioids are 
prescribed, the patient and any Caretaker should be counseled on safe ways to store and 
dispose of medications. 
Appropriate goals of pain treatment include: reasonable attainable improvement 
in pain and activity; improvement in pain-associated problems such as sleep disturbance, 
depression, and anxiety; and avoidance of unnecessary or excessive use of medications.  
Individualized goals for pain relief and improved physical, functional and psychosocial 
activity should be set to help guide the choice and response to treatment.  The treatment 
plan should contain information supporting the selection of pharmacologic and non 
pharmacologic control of pain and achievement of specific physical, functional and 
psychosocial activity goals.  The plan should document any further diagnostic 
evaluations, consultations or referrals, and/or additional therapies that have been 
considered, including any follow up plans.  A prescriber may reduce risks of abuse, 
misuse, diversion, and/or unintentional overdose by incorporating a schedule for 
reassessment and re-evaluation in the treatment plan, as discussed in Periodic Review 
herein below. 
Informed Consent and Treatment Agreement 
Use of a written informed consent, memorializing the joint decision to prescribe, 
and a treatment agreement, memorializing the treatment plan and goals, is the standard of 
care. They may be combined into one document for convenience.  Informed consent 
should always be considered for higher dose or ongoing acute or chronic pain opiate 
prescribing. 
Informed consent documents typically address: 
 The potential risks and anticipated benefits of chronic opioid therapy; 
 Potential short and long term side effects of the medication, such as constipation 
and cognitive impairment; 
 The likelihood that tolerance to and physical dependence on the medication will 
develop; 
 The risk of drug interactions and over-sedation, including the increased risk of 
using opiates in disease and conditions such as obesity and sleep apnea; 
 The risk of impaired motor skills affecting driving and other tasks; 
 The risk of opioid misuse, dependence, addiction and overdose; 
 The limited evidence of the benefit of long-term opioid therapy; 
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 The prescriber’s policies and expectations, including the number and frequency of 
prescription refills, early refills, and replacement of lost or stolen medications; 
and 
 Specific reasons for which drug therapy may be changed or discontinued, 
including violation of the policies and agreements spelled out in the treatment 
agreement. 
Treatment agreements outline the joint responsibilities of the prescriber and the 
patient in the management of chronic pain and may be applicable in some cases of acute 
pain.  Treatment agreements are indicated when opioid or other abusable medications are 
prescribed.  Agreements typically discuss: 
 The treatment goals for pain management, restoration of activities, and safety; 
 The patient’s responsibility for using medication safely, including not using more 
medication than prescribed, not using an opioid in combination with alcohol or 
other potentially dangerous substances, storing medications in a secure location, 
and safely disposing of unused medication; 
 The patient’s responsibility to obtain opioids from only one prescriber or practice 
and to fill prescriptions at an in-state pharmacy or one that participates in 
SCRIPTS reporting; 
 The patient’s agreement to submit to periodic drug testing of blood, urine, hair, 
saliva, or other body material;  
 The prescriber’s responsibility to be available or to have a covering prescriber be 
available to care for unforeseen problems and to prescribe scheduled refills; and 
 The prescriber’s responsibility to provide referrals to substance abuse counseling 
when abuse potential is present and for failed drug screens. 
Initiating an Opioid Trial 
Safer alternative treatments should be considered before initiating opioid therapy.  
When the decision to use an opiate has been made, it should be presented to the patient as 
a therapeutic trial to test for a defined period of time, usually no more than ninety (90) 
days, and with specified evaluation points.  The prescriber should explain that progress 
will be carefully monitored for benefit and harm in terms of the effect of opioids on the 
patient's level of pain, physical function and psychosocial activities.  Attention will be 
focused on adverse events and risks to safety.  Prescribers should develop and implement 
appropriate safe practices for patients identified as at risk for misuse, abuse, diversion, 
and/or overdose.  At risk patients should be candidates for abuse deterrent formulations 
of the prescribed opioid. 
The lowest dose possible should be given to an opioid naive patient at the 
beginning of opioid therapy and titrated to effect while monitoring for complication.  
Opioid therapy should begin with a short acting drug and rotate to a long acting/extended 
release, if indicated.  A decision to continue opioid therapy beyond the trial period should 
reflect a careful evaluation of benefits, adverse events, and potential risks. 
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Periodic Review 
As stated previously, review of SCRIPTS data at the time of clinical exam and 
prescription writing of opiates is the standard of care.  The prescriber should regularly 
review the patient’s progress, including any new information about the etiology of the 
pain or the patient’s overall health and level of activities.  When possible, collateral 
information about the patient’s response to opioid therapy, including the medication’s 
affect on physical, functional, and psychosocial activities, as well as signs of adverse 
effects, such as sedation or other impairment, should be obtained from family members 
or other close contacts.  The prescriber should regularly review SCRIPTS data.  The 
patient should be seen more frequently while the treatment plan is being initiated and 
when the opioid dose is being adjusted.  As the patient is stabilized in the treatment 
regimen, follow up visits may be scheduled less frequently. 
Continuation, modification or termination of opioid therapy for pain should be 
contingent on the prescriber’s evaluation of the patient’s progress toward treatment goals 
and assessments of substantial risks or adverse events.  A satisfactory response to 
treatment would be indicated by a reduced level of pain and improved physical, 
functional, and psychosocial activities.  Use of measurement tools to assess the patient’s 
level of pain, activity, and quality of life can be helpful in documenting therapeutic 
outcomes. 
Risks associated with opioids increase with escalating doses.  When a patient is 
prescribed 80 Morphine Equivalent Dose (MED) for longer than three continuous 
months, it is recommended that the prescriber: re-establish informed consent; review the 
patient’s functional status, including daily activities, analgesia, aberrant behavior, and 
adverse effects, as it relates to progress toward treatment objectives established at the 
onset of opioid therapy; consult SCRIPTS to verify compliance; re-establish office visit 
intervals; review frequency of drug screens; and review and execute a new treatment 
agreement.  Relevant information from SCRIPTS should become part of the patient’s 
medical record. 
The prescriber should avoid opiate dose escalation without adequate attention to 
risks or alternative treatments.  The prescriber should be mindful that not all pain can be 
alleviated through the use of opioids.  Clinicians should avoid over-reliance on opioids as 
the primary or only treatment modality, including using opioid dose escalation as the only 
response to a complaint of inadequate pain relief.  The prescriber should be continuously 
attentive to the use of opiates in the presence of other comorbidities, such as mental 
illness, respiratory disorders and sleep apnea, and a pre-existing substance use disorder.  
The prescriber should dispel any mistaken expectation that complete eradication of pain 
is an attainable goal when a reasonable level of discomfort is the best clinical outcome a 
patient may achieve. 
Prescribers should reconsider a referral to one or more other providers 
specializing in the treatment of the area, system or organ of the body perceived to be the 
source of the patient’s pain.  This may include consultation with a pain specialist if the 
prescriber is not a pain specialist. 
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Periodic Drug Testing 
Periodic drug testing may be useful in monitoring adherence to the treatment plan, 
as well as in detecting the use of non-prescribed drugs.  Drug testing is an important 
monitoring tool because self-reports of medication use and behavioral observations are 
not always reliable.  Urine may be the preferred biologic specimen for testing because of 
its ease of collection and storage and the cost-effectiveness of such testing.  When testing 
is conducted as part of a pain treatment plan, forensic standards are generally not 
employed.  Sample collection may not need to be observed and chain-of-custody 
protocols are not customarily followed.  Initial testing may be done using class-specific 
immunoassay point-of-care or laboratory-based test.  These tests do not typically identify 
a particular specific drug within a class.  However, the tests are available as panels and 
immunoassays for specific drugs can be included.  It is important that the clinician 
formulate these panels to include the specific medications being prescribed, and, if 
possible, the drugs commonly abused in the local community.  If necessary, initial testing 
can be followed with more specific techniques, including gas chromatography/mass 
spectrometry (GC/MS) or other chromatographic tests.  It is important to identify the 
specific drug, not just the class of the drug, when drug testing a pain patient. 
Prescribers should be knowledgeable about the specific drug tests they order.  
They should be aware of the limitation, sensitivity and specificity of the tests they order 
and take care to order tests appropriately.  When a drug test is ordered, it is important to 
specify that it include the opioid being prescribed.  Because of the complexities involved 
in interpreting drug test results appropriately, it is advisable to confirm significant or 
unexpected results with the testing laboratory's toxicologist or a clinical pathologist. 
Test results that suggest illicit or prescribed medication misuse should be 
discussed with the patient.  Results of drug testing and subsequent discussion with the 
patient should be documented in the medical record. 
If the patient’s progress is unsatisfactory, the prescriber must decide whether to 
revise or augment the treatment plan, whether other treatment modalities should be added 
to or substituted for the opioid therapy, or whether a different approach, possibly 
involving a referral to a pain specialist or other health professional, should be employed. 
Drug Diversion 
Documented drug diversion or prescription forgery, obvious impairment, and 
abusive or assaultive behaviors require an immediate response.  Failure to respond can 
place the patient and others at significant risk of adverse consequences, including 
accidental overdose, suicide attempt, arrest and incarceration or death.  For this reason, 
prescribers who prescribe chronic opioid therapy should be knowledgeable about 
substance use disorders and be able to distinguish substance use disorder from physical 
dependence on opiates.  Detection of opioid diversion is one of the most difficult duties a 
prescriber has.  The combination of periodic, unscheduled and random pill counting and a 
concomitant UDS with a confirmation is an effective way to ascertain whether a patient is 
diverting. 
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Warning signs that a patient may be seeking opioid medications for reasons other 
than legitimate pain relief include: 
Suspicious history: 
 Patient referred is already taking controlled substances, especially a combination 
of narcotics, muscle relaxants, and sedative/hypnotics; 
 Soft diagnosis, perhaps based solely on chief complaint; 
 Multiple doctors and pain physicians in the past; 
 Patient travelled out of the way to come to your clinic; 
 Solicitous behavior (―You’re the best. I always wanted to come to you.‖); 
 No past medical records are provided and patient states he is unable to obtain 
records from ―referring doctor‖; 
 Patient brings records that look old, tattered or suspicious in some other way; or 
 Patient asks for a specific controlled substance (example: prefers LortabⓇ over 
Norco). 
Suspicious physical exam: 
 No abnormal findings; 
 Abnormal findings in exam room inconsistent with witnessed behavior (For 
example, the patient has normal gait from car to office door, but limps once inside 
door.); 
 Exaggerative behaviors, pain is always a 10 on a scale of 1 to 10; 
 Unimpressive imaging; 
 Presence of injecting behavior (old or recent ―track marks‖ or multiple healed or 
current abscesses) or marked nasal erythema from insufflation (snorting); or 
 Patient smells like marijuana smoke. 
Equivocal compliance: 
 SCRIPTS shows multiple providers, multiple pharmacies, prescriptions for 
multiple types of medications, and prescriptions from out of area doctors, etc. 
 UDS is refused or abnormal, for which patient offers multiple excuses, or detects 
any illegal substance; 
 Inconsistent tests results over time; 
 Patient seeks recurrent early refills for lost or stolen prescriptions or for increased 
opioid use without consultation with prescriber; or 
 Patient has excuses for lost pills. 
No or equivocal clinical improvement: 
 Subjective improvement alone does not count; 
 Lack of evidence of objective improvement in physical, functional and 
psychosocial activities; or 
 Lack of evidence of decreasing use of opioid medications, decreasing visits to 
emergency rooms, etc. 
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What you should do when the clinician suspects misuse, abuse or addiction: 
 Request picture I.D. or other I.D. and a Social Security Number. Photocopy these 
documents and include in the patient’s record; 
 Call a previous practitioner, pharmacist or hospital to confirm the patient’s story; 
 Confirm a telephone number, if provided by the patient; 
 Confirm the current address at each visit; 
 Investigate suspicions further by presenting and discussing specific concerns with 
the patient, re-checking SCRIPTS data, increasing the use of drug screens, and 
talking with family members; 
 Write prescriptions for limited quantities until conflicts are resolved and it is safe 
to do so;  
 Increase frequency of visits and drug screens; and 
 Document all activities in support of mitigating potential misuse, abuse, or 
addiction. 
Consultation and Referral 
The treating prescriber should seek a consultation with or refer the patient to a 
pain, psychiatric, addiction, or other mental health specialist as needed.  A patient who 
has a history of substance use disorder or a co-occurring mental health disorder may 
require specialized assessment and treatment. 
Prescribers who prescribe chronic opioid therapy should be familiar with 
treatment options for opioid addiction, including those available in licensed opioid 
treatment programs (OTPs) and those offered by an appropriately credentialed and 
experienced physician through office-based opioid treatment (OBOT), so as to make 
appropriate referrals when needed. 
Discontinuing Opioid Therapy 
The prescriber and patient should regularly weigh the potential benefits and risks 
of continued treatment and determine whether such treatment remains appropriate.  
Opioids should be tapered or discontinued when a patient’s pain is poorly controlled on 
appropriate doses of medication or if when opioid treatment produces no improvement in 
physical, functional, or psychosocial activity.  Reasons for discontinuing opioid therapy 
include resolution of the underlying painful condition, emergence of intolerable side 
effects, inadequate analgesic effect, deteriorating physical, functional or psychosocial 
activities or significant aberrant medication use. 
If opioid therapy is discontinued in the setting of appropriate use, but inadequate 
response, and the patient has become physically dependent, they should be provided with 
a safely structured tapering regimen.  In the setting of abuse or addiction, when it is 
necessary to discontinue opioids quickly because of safety, withdrawal can be managed 
either by the prescriber or by referring the patient to an addiction specialist.  The 
termination of opioid therapy should not mark the end of treatment, which should 
continue with other modalities, either through direct care or referral to other health care 
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specialists, as appropriate.  The discontinuation of opioid therapy where continuation is 
not clinically indicated does not constitute patient abandonment. 
Medical Records 
Every prescriber who treats patients for pain must maintain accurate and complete 
medical records.  The medical record should include the following: 
 Copies of the signed consent and/or treatment agreement as appropriate for level 
of treatment; 
 The patient’s medical history; 
 Results of the physical examination and all laboratory tests; 
 Results of the risk assessment, including results of any screening instruments 
used; 
 A description of the treatment provided, including all medications prescribed or 
administered (including date, type, dose, and quantity.); 
 SCRIPTS data; 
 Instructions to the patient, including discussions of risks and benefits with the 
patient and any significant others; 
 Results of ongoing monitoring of patient progress in terms of pain management 
and physical, functional and psychosocial improvement; 
 Notes on evaluation by and consultations with specialists; 
 Any other information used to support the initiation, continuation, revision or 
termination of treatment and the steps taken in response to any aberrant 
medication use behaviors.  These may include actual copies of, or references to, 
medical records of past hospitalizations or treatments by other providers; 
 Authorization for release of medical information to other treatment providers; and 
 All prescription orders for opioid analgesics and other controlled substances, 
whether written or telephoned. In addition, written instructions for the use of all 
medications should be given to the patient and documented in the record.  The 
name, telephone number, and address of the patient’s pharmacy should also be 
recorded in an accessible manner so as to be readily available for review. 
Good records demonstrate that a medically necessary service was provided to the 
patient.  Even if the outcome is less than optimal, thorough records protect both the 
prescriber and the patient. 
B. TREATMENT OF ACUTE PAIN 
Acute pain was defined historically simply in terms of duration.  It is now viewed 
as a complex, unpleasant experience with emotional and cognitive, as well as sensory, 
features that occur in response to tissue trauma.  In contrast to chronic pain, relatively 
high levels of pathology usually accompany acute pain.  Acute pain resolves with healing 
of the underlying injury.  Acute pain is usually nociceptive, but may be neuropathic.  
Common sources of acute pain include trauma, surgery, labor, medical and dental 
procedures and acute disease states. 
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Acute pain, by definition, does not last longer than six months and resolves when 
the underlying cause of pain has been treated or healed.  An accurate assessment of acute 
pain should be performed when a patient presents with pain to the health care setting.  A 
solid understanding of the patient and the etiology of the pain are essential for the 
development of an effective and appropriate short-term pain management plan. 
Recommendations for Treatment of Acute Pain: 
 Develop an office policy for opioid prescribing and have this clearly posted and 
available for patients; 
 Perform a thorough history and physical at the onset; 
 Utilize SCRIPTS data as part of every patient’s initial evaluation prior to 
prescribing opiates.  Failure to utilize SCRIPTS to assess risk of opiate/sedative 
prescribing may be considered misconduct by the responsible regulatory board, 
depending upon the clinical situation.  
 Maintain accurate and complete medical records that include all of the 
components outlined above in the Chronic Pain section. 
 Evaluate acute pain patients frequently for physical, functional and psychosocial 
improvement, with adjustment to treatment as needed.  It is generally 
contraindicated to include refills on opioid prescriptions for acute pain; 
 Educate your patients about pain and analgesia.  Explain the underlying diagnosis 
causing the pain, the natural history of the condition, and how your patient can 
help the healing process; 
 Exhaust non-opioid medications and collaborate with other professionals, 
including physical therapists and pain specialists, if possible.  Consider 
nontraditional therapies such as acupuncture and massage therapy; 
 Prescribe a complete pain management program when an opioid is used to treat 
acute pain: utilize NSAIDS, develop and recommend specific exercises, and 
utilize other modalities (e.g. heat, ice, massage, topical medications); 
 Prescribe opioids intentionally.  With the first opioid prescription, set patient 
responsibilities and the expectation that opioids will be discontinued when the 
pain problem has resolved or is not responding to what you are doing; 
 Write the taper on the prescription (e.g., po every 6 hours for 3 days, po every 
hours for days, po every 24 hours for 3 days, stop); 
 Do not prescribe long-acting or controlled-release opioids (e.g. long-acting 
oxycodone and oxymorphone, fentanyl patches, long-acting hydromorphone and 
morphine or methadone) for acute pain; 
 Consider performing risk stratification, including urine drug monitoring, after 
accessing SCRIPTS at the onset of pain care; 
 Clearly instruct patients to take opiates only as prescribed, not more frequently or 
in greater quantities.  Educate your patients about the risks of taking opioid 
analgesics, including, but not limited to:  overdose that can slow or stop their 
breathing and even lead to death; fracture from falls especially in patients over 60; 
drowsiness leading to injury, especially when driving or operating heavy or 
dangerous equipment; and tolerance and addiction.  Educate your patients about 
acute pain – tell them it is likely that their acute pain will diminish and resolve, 
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and tell them that prolonged use of scheduled opioids may actually impair their 
ability to fully recover; 
 Advise patients to avoid medications that are not part of their treatment plan 
because they may worsen the side effects and increase the risk of overdose from 
opiates; 
 Prepare patients that it may be difficult to taper off opioids, particularly from 
higher dose regimens, even when they are eager to do so; 
 Consider referrals and consultations with a pain specialist if the patient is not 
responding to your treatment plan.  You may want to do this early in the course of 
treatment if the patient does not respond to standard first line medications and 
before you prescribe narcotics.  Pain specialists may offer procedures or other 
interventions that will help your patient improve and avoid unnecessary opiate 
use; and 
 Assure that patients are provided with easy to follow and graduated activity 
instructions that help them quickly improve their quality of life in physical, 
functional and social domains. 
C. TREATMENT OF PAIN IN THE EMERGENCY DEPARTMENT 
Emergency medical physicians practice in a unique clinical setting, whereby the 
urgency of the healthcare services available naturally render the practitioners  prime 
targets for patients seeking prescriptions for opioids for non-medical reasons.  In addition 
to the emergent nature of the patient encounters, these practitioners often must treat 
patients without the benefit of prior medical records, creating a higher probability of 
presentation with an incomplete or inaccurate medical history. These factors necessitate 
the identification of additional prescribing considerations: 
 Emergency medical prescribers are reminded that patterns of prescription of 
opiate/sedative medications in quantities or frequencies excessive of what may be 
considered reasonable by prudent emergency physicians practicing in a similar 
circumstance may be considered misconduct by the responsible regulatory board; 
 Emergency medical prescribers should maintain a high index of suspicion for 
potential diversion or abuse of their prescriptions, and should utilize SCRIPTS 
data and consult with a patient’s primary opioid prescriber, as feasible, prior to 
prescribing opiate/sedative medications when there is a suspect clinical 
presentation or in the circumstance of chronic pain management.  If a rare case 
should occur where such a prescription is indicated, only a quantity sufficient to 
prevent morbidity until the patient’s primary provider can be seen should be 
provided; 
 Emergency medical prescribers should not provide replacement prescriptions for 
controlled substances that were lost, destroyed or stolen; 
 Emergency medical prescribers should not provide replacement doses of 
methadone for patient in a methadone treatment program; 
 Long-acting or controlled-release opioids (such as OxyContinⓇ, fentanyl patches 
and methadone) should not be prescribed routinely by emergency department 
prescribers, and then only in a quantity sufficient to prevent morbitiy until the 
patient’s primary provider can be seen; 
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 Emergency department prescribers should utilize SCRIPTS data prior to 
prescribing opioids.  Failure to utilize SCRIPTS to assess risk of opiate/sedative 
prescribing may be considered misconduct by the responsible regulatory board, 
depending upon the clinical situation as documented in the patient’s medical 
record; 
 All prescribers who manage patients with chronic pain should be encouraged to 
send patient agreements to local emergency departments for reference, and work 
to develop appropriate plans for the evaluation and management of their patients 
in the emergency department in conjunction with emergency department 
prescribers; 
 Prescriptions for opioid pain medication from emergency department providers 
for acute injuries, such as fractured bones, should not exceed a five day supply in 
most cases; and 
 When appropriate, emergency department patients should be screened for 
substance abuse prior to receiving a prescription for opioids for acute pain 
management. 
III. INAPPROPRIATE TREATMENT OF PAIN 
The inappropriate treatment of pain includes nontreatment, under treatment, 
overtreatment and the continued use of ineffective treatments.  Inappropriate pain treatment may 
result from a prescriber’s lack of knowledge about pain management.  Fear of investigation or 
sanction by federal, state and local agencies may also result in inappropriate treatment of pain.  
Appropriate pain management is the treating prescriber’s responsibility.  Accordingly, the 
appropriate regulatory board will consider a departure from standards of practice to be the 
inappropriate treatment of pain and will investigate such allegations, recognizing that some types 
of pain cannot be completely relieved, and taking into account whether the treatment is 
appropriate for the diagnosis. 
While acknowledging that undertreatment of pain exists in certain instances, it must be 
understood that chronic pain often is intractable, that the current state of medical knowledge and 
medical therapies, including opioid analgesics, does not provide for complete elimination of 
chronic pain in most cases, and that the existence of persistent and disabling pain does not in and 
of itself constitute evidence of undertreatment. 
Circumstances that contribute to both the inadequate treatment of pain and the 
inappropriate prescribing of opioid  may include:  (1) prescriber’s lack of knowledge as to 
prevailing best clinical practices; (2) inadequate research into the sources of and treatments for 
pain; (3) sometimes conflicting clinical guidelines for appropriate treatment of pain; (4) 
prescriber’s concern that prescribing needed amounts of opioid analgesics will result in added 
scrutiny by regulatory authorities; (5) prescriber’s misunderstanding of causes and 
manifestations of opioid dependence and addiction; (6) prescriber’s fear of causing addiction or 
being deceived by a patient who seeks drugs for purpose of misuse; (7) prescriber’s practice 
outside the bounds of professional conduct by prescribing opioid analgesics without a legitimate 
medical purpose; and (8) inadequate prescriber education about regulatory policies and 
processes. Inappropriate treatment also can result from a mistaken belief on the part of patients 
and their prescribers that complete eradication of pain is an attainable goal, and one that can be 
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achieved without disabling adverse effects.  Additionally, treatment options may be limited 
based on availability and/or health plan policies on covered benefits or drug formularies. 
IV. ACTIONS OUTSIDE THE SCOPE OF APPROPRIATE PAIN MANAGEMENT 
The applicable regulatory boards will consider a departure from accepted best clinical 
practices for the management of pain, particularly chronic pain, to be improper, including, but 
not limited to the following: 
 Inadequate attention to initial assessment to determine if opioids are clinically 
indicated and to determine the risks associated with their use in a particular 
individual with pain:  There are significant risks associated with opioids; therefore, 
benefits must outweigh the risks. 
 Inadequate monitoring during the use of potentially abusable medications:  
Opioids may be associated with addiction, drug abuse, aberrant behaviors, chemical 
coping and other dysfunctional behavioral problems.  Some patients may benefit from 
opioid dose reductions or tapering or weaning off the opioid. 
 Inadequate attention to patient education and informed consent:  The decision to 
begin opioid therapy for chronic pain should be a shared decision of the prescriber 
and patient after a discussion of the risks and a clear understanding that the clinical 
basis for the use of these medications for chronic pain is limited, that some pain may 
worsen with opioids, and that taking opioids with other substances or certain 
conditions (i.e. sleep apnea, mental illness, pre-existing substance use disorder) may 
increase risk. 
 Unjustified dose escalation without adequate attention to risks or alternative 
treatments:  Risks associated with opioids increase with escalating doses as well as 
in the presence of other comorbidities (i.e., mental illness, respiratory disorders, pre-
existing substance use disorder and sleep apnea) and with concurrent use with 
respiratory depressants, such as benzodiazepines or alcohol. 
 Excessive reliance on opioids, particularly high dose opioids for chronic pain 
management:  Prescribers should be prepared for risk management with opioids in 
advance of prescribing and should use opioid therapy for chronic noncancerous pain 
only when safer and reasonable effective options have failed.  The prescriber should 
maintain the lowest opioid dosage possible and continue only if clear and objective 
outcomes are being met. 
 Not making use of available tools for risk mitigations:  SCRIPTS should be 
utilized prior to prescribing opioids and for ongoing monitoring. 
The appropriate regulatory board will judge the validity of the prescriber’s treatment of 
the patient based on available documentation, rather than solely on the quantity and duration of 
medication administered.  The goal is to control the patient’s pain while effectively addressing 
other aspects of the patient’s functioning, including physical, psychological, social and work-
related factors. 
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The appropriate evaluation and management of a patient’s pain, including the 
prescription of opiate medications, is the treating prescriber’s responsibility.  Prescribers should 
not fear disciplinary action from the respective regulatory board for ordering, prescribing, 
dispensing or administering controlled substances, including opioid analgesics, for a legitimate 
medical purpose and in the course of professional practice, when current best clinical practices 
are met.  In fact, the regulatory body will consider the failure to prescribe controlled substances 
responsibly to be a departure from the standards of practice and will investigate such allegations, 
utilizing current clinical practice guidelines and expert review in determining whether or not 
standard of care have been met. 
Allegations of inappropriate pain management will be evaluated on a case by case basis.  
The regulatory board may not necessarily take disciplinary action against a prescriber for 
deviating from these guidelines when contemporaneous medical records document reasonable 
cause for deviation.  The prescriber’s conduct will be evaluated by the outcome of pain 
treatment, recognizing that some type of pain cannot be completely relieved, and by taking into 
account whether the drug used is appropriate for the diagnosis, as well as improvement in patient 
function and/or quality of life. 
V. SPECIAL CONSIDERATIONS 
Compliance with Controlled Substances Laws and Regulations 
In order to dispense or administer controlled substances, the prescriber must be registered 
with the DEA, licensed by the state in which he or she practices, and in compliance with 
applicable federal and state regulations.  Prescribers are referred to the Physician’s Manual of the 
US.S Drug Enforcement Administration for specific rules and regulations governing the use of 
controlled substances; relevant provisions of the South Carolina Dental Practice Act, the South 
Carolina Medical Practice Act, and the South Carolina Nurse Practice Act; relevant regulations 
promulgated by the regulatory authorities governing these professions; and advisory opinions 
issued by the regulatory authorities governing these professions. 
Naloxone 
Patients prescribed more than 80 mg MED are at an increased risk of death from 
respiratory depression.  These patients require closer monitoring and other respiratory 
depressants, such as alcohol and benzodiazepines, should be avoided.  The Board recognizes that 
a prescription of Naloxone may be appropriate in certain situations involving patients who are 
prescribed high dose opioids or are more vulnerable to the risk of opioid overdose due to co-
morbidities or other factors.  Whether Naloxone is medically necessary for a particular patient is 
within the discretion of the patient’s primary opioid prescriber. 
Pregnancy 
When treating females of childbearing age, prescribers must consider pregnancy or the 
risk of pregnancy and provide appropriate counseling before prescribing opioids.  Female 
patients of childbearing age should be counseled regarding the risks of opioid use during 
pregnancy, the effect of chronic opioid therapy on the neonate (neonatal abstinence syndrome) 
and the consideration for a  high risk obstetrical consult prior to attempting conception. 
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Telemedicine 
Chronic pain shall not be treated by the use of controlled substances through 
telemedicine. 
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DEFINITIONS 
Abuse:  A term with a wide array of definitions depending on the context.  The American 
Psychiatric Association defines drug abuse as ―a maladaptive pattern of substance use, leading to 
clinically significant impairment or distress, as manifested by one or more behaviors.‖  The 
DSM-V replaces the term ―abuse‖ with ―misuse.‖  In addition, Substance abuse (SA) can mean 
the use of any substance(s) for non-therapeutic purposes, or use of medication for purposes other 
than those for which it is prescribed.  The medical diagnosis of SA is defined by any one of the 
following four criteria during a 12-month period:  (1) failure to fulfill major obligations at work, 
school, or home; (2) recurrent use in situations in which it is physically hazardous; (3) recurrent 
substance-related legal problems; (4) continued use despite persistent social or interpersonal 
problems.  Substance abuse can lead to substance dependence. 
Acute pain:  The normal, predicted physiological response to a noxious chemical, thermal, or 
mechanical stimulus and typically is associated with invasive procedures, trauma, and disease. 
Acute pain is generally time-limited.  Duration of acute pain generally coincides with the time 
frame of normal healing, and serves to protect and injured body segment. 
Addiction:  A primary, chronic, neurobiological disease with genetic, psychosocial, and 
environmental factors influencing its development and manifestations.  Addiction is 
characterized by behaviors that include the following: impaired control over drug use, craving, 
compulsive use, continued use despite harm.  Physical dependence and tolerance are normal 
physiological consequences of extended opioid therapy for pain and are not the same as 
addiction. 
Chronic pain:  The state in which pain persists beyond the usual course of an acute disease or 
healing of an injury or that may or may not be associated with an acute or chronic pathological 
process that causes continuous or intermittent pain over months or years. 
Dependence or Physical dependence:  A state of adaptation that is manifested by drug class-
specific signs and symptoms that can be produced by abrupt cessation, rapid dose reduction, 
decreasing blood level of drug, and/or administration of an antagonist.  Physical dependence, by 
itself, does not equate with addiction.  The medical diagnosis of Substance Dependence (SD) is 
defined by any three of the following seven criteria during a 12-month period:  (1) tolerance; 
(2)withdrawal; (3) substance often taken in large amounts or over longer period than intended; 
(4) persistent desire or unsuccessful efforts to cut down or control use; (5) great deal of time 
spent in activities necessary to obtain, use, or recover from the substance; (6) important social, 
occupational, or recreational activities given up or reduced; (7) continued use despite knowledge 
of having persistent or recurrent physical or psychological problem likely to have been caused or 
exacerbated by the substance. 
Diversion:  The use of prescriptions drugs for recreational consumption, i.e. diverting them from 
their original medical purpose.  The Federal Controlled Substances Act (CSA) establishes a 
closed system of distribution for drugs classified as controlled substances.  Records must be kept 
from the time a drug is manufactured to the time is it dispensed.  Any pharmaceutical which 
escapes the closed system is said to have been ―diverted‖ and is illegal.  Those people who 
―diverted‖ the drug are in violation of the law.  Conversely, drug diversion may also refer to 
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legal programs which educate, rehabilitate, and ―divert‖ first-time drug offenders from jail and 
their original destructive life course. 
Misuse or non-medical use:  Incorporates all uses of a prescription medication other than those 
that are directed by a prescriber and used by a patient within the law and requirements of good 
medical practice. 
Opioid abuse/dependence:  Repeated use of a drug while producing problems in three or more 
areas over a 12-month period.  Areas include tolerance, withdrawal, overdose, and use despite 
impending consequences.  The most commonly abused opioid is oxycodone from diverted 
prescriptions.  Others include, but are not limited to, hydrocodone, morphine, meperidine, 
fentanyl, methadone, buprenorphine, butorphanol, tramadol and pentazocine. 
Pain:  An unpleasant sensory and emotional experience associated with actual or potential tissue 
damage or described in terms of such damage.  Pain is a complex experience embracing physical 
mental, social and behavioral processes, compromising the life of many individuals. 
Prescriber:  A health care practitioner licensed by the State of South Carolina and authorized to 
prescribe medications, including physicians, physician assistants, dentists and advanced practice 
nurses with prescriptive authority. 
Pseudoaddiction:  The iatrogenic syndrome resulting from the misinterpretation of relief 
seeking behaviors as though they are drug seeking behaviors that are commonly seen with 
addiction.  The relief seeking behaviors of pseudoaddiction resolve upon institution of effective 
analgesic therapy.  Addiction and pseudoaddiction can both occur in the same person. 
Tolerance:  A physiological state resulting from regular use of a drug in which an increased 
dosage is needed to produce a specific effect.  Or, a reduced effect is observed with a constant 
dose over time.  Tolerance may, or may not, be evident during opioid treatment and does not 
equate with addiction.  Tolerance can occur to an opioid’s analgesic effects and to its unwanted 
side effects, i.e., sedation and nausea.  Physiologically, when using a drug like alcohol, nicotine, 
some prescription medications, or opioids, changes take place in the brain.  Over time, these 
changes reduce natural dopamine production and reduce the brain’s ability to respond to 
dopamine.  An addict will perceive this relative lack of dopamine in the brain as increased 
tolerance and he/she will often counter it with increased drug use. 
Trial period:  The period of time when medication or other treatment efficacy is tested to 
determine whether treatment goals can be met.  If goals cannot be met, the trial is discontinued 
and an alternate treatment may be considered. 
Withdrawal:  If drug use is stopped abruptly, a withdrawal syndrome can occur where adaptive 
body responds, originally present to counter and detoxify the drug, become unopposed and often 
produce a painful experience for the drug user.  Withdrawal is the cardinal sign of physical 
dependence on a drug. 
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APPENDIX D 
DATA COMMITTEE ANALYSIS 
Policy 
Track 
Measurement Is this 
currently 
measured? 
Does a 
database 
currently 
contain this 
info?  If 
yes, which? 
If currently 
measured, 
baseline 
measurement 
What are 
gaps in 
existing 
data? 
If not 
measured 
how can we 
measure? 
What 
additional 
information is 
necessary for 
an accurate 
measurement? 
Action Steps 
to Improve 
Statistic 
Responsible 
Party 
Legislative 
Action 
Required? 
I. 
Pharmacy 
1. Number of  
In-state 
Pharmacies in 
Compliance with 
Daily Reporting 
Requirement 
Yes PMP # of pharmacies 
registered - 85% 
of 1,147 in-state 
pharmacies 
registered w/ 
BDC 
October 2014 
Getting 
reports and 
time to drill 
down; 
≥1,100 
pharmacies 
reporting 
N/A ARCOS report 
from DEA 
(Automation 
of Reports & 
Consolidated 
Orders 
System) 
ARCOS 
report 
DHEC No 
 2. Number of 
pharmacists 
enrolled in 
PMP 
Yes PMP # of 
pharmacists 
enrolled – 
2,326 
September 30, 
2014 
N/A N/A N/A N/A DHEC No 
 3. Annual # of 
queries in PMP 
by RPhs 
Yes – can be 
tracked via 
report 
PMP 304,647 
Time frame: 
July 1, 2013 – 
June 30, 2014 
N/A N/A N/A N/A DHEC No 
 4. Annual # of 
queries in PMP 
by 
practitioners 
Yes – can be 
tracked via 
report 
PMP 309,852 
Time frame: 
July 1, 2013 – 
June 30, 2014 
N/A N/A N/A N/A DHEC No 
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Policy 
Track 
Measurement Is this 
currently 
measured? 
Does a 
database 
currently 
contain this 
info?  If 
yes, which? 
If currently 
measured, 
baseline 
measurement 
What are 
gaps in 
existing 
data? 
If not 
measured 
how can we 
measure? 
What 
additional 
information is 
necessary for 
an accurate 
measurement? 
Action Steps 
to Improve 
Statistic 
Responsible 
Party 
Legislative 
Action 
Required? 
II. 
Prescription 
Drug 
Monitoring 
1. # of 
opioids* 
prescribed 
annually, by 
county 
See attached 
Yes PMP Time frame: 
July 1, 2013 – 
June 30, 2014 
N/A N/A N/A N/A DHEC No 
 2. # of 
benzodiaze-
pines* 
prescribed 
annually, by 
county 
See attached 
Yes PMP Time frame: 
July 1, 2013 – 
June 30, 2014 
N/A N/A N/A N/A DHEC N/A 
 3. # of deaths 
(annually) 
attributable to 
prescription 
drug 
overdose/ 
abuse (adult 
and youthful 
populations) 
Currently 
captured, 
but not 
uniformly or 
with same 
category 
reported 
WebDeath N/A Absence of 
uniformity 
in reporting 
N/A Perhaps a 
simple form 
like the SLED 
form used in 
mass fatalities 
Additional 
resources 
needed: 
People, 
Software & 
Training 
S.C. 
Coroners 
Perhaps, 
for 
allocation 
of 
resources 
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Policy 
Track 
Measurement Is this 
currently 
measured? 
Does a 
database 
currently 
contain this 
info?  If 
yes, which? 
If currently 
measured, 
baseline 
measurement 
What are 
gaps in 
existing 
data? 
If not 
measured 
how can we 
measure? 
What 
additional 
information is 
necessary for 
an accurate 
measurement? 
Action Steps 
to Improve 
Statistic 
Responsible 
Party 
Legislative 
Action 
Required? 
 4. # of 
“frequent 
flyer” letters 
sent to 
prescribers by 
DHEC, by 
county 
No.  DHEC 
concluded 
this is 
beyond the 
current 
scope of 
authority. 
N/A N/A N/A N/A N/A N/A DHEC, if 
authorized 
Yes 
 5. # of 
prescribers 
referred to LLR 
by DHEC for 
potential 
improper 
prescribing 
patters (Data 
Committee 
suggests 
tracking this by 
all sources, not 
just DHEC.) 
No.  LLR 
doesn’t 
currently 
track the 
source of 
complaints. 
Yes, 
RELAES 
N/A N/A Need to 
reformat 
data entry 
in RELAES 
to capture 
this data 
Complaint 
source 
Review 
RELAES to 
determine 
whether 
this can be 
extracted; 
adopt new 
data entry 
process 
LLR No 
 S.C. State Plan to Prevent and Treat Prescription Drug Abuse – December 2014 112 
 
Policy 
Track 
Measurement Is this 
currently 
measured? 
Does a 
database 
currently 
contain this 
info?  If 
yes, which? 
If currently 
measured, 
baseline 
measurement 
What are 
gaps in 
existing 
data? 
If not 
measured 
how can we 
measure? 
What 
additional 
information is 
necessary for 
an accurate 
measurement? 
Action Steps 
to Improve 
Statistic 
Responsible 
Party 
Legislative 
Action 
Required? 
 6. # of patients 
flagged by 
DHEC as 
potential 
“doctor 
shoppers” or 
drug abusers, 
by county 
No one has 
officially 
defined 
parameters 
for “doctor 
shopper,” 
but PMP can 
run a report 
once 
parameters 
are set. 
PMP 
contains this 
information, 
but needs 
parameters 
to run 
report. 
N/A Reporting 
criteria 
Establish 
reporting 
criteria 
Reporting 
criteria 
Establish 
reporting 
criteria 
DHEC No 
 7. # of 
pharmacists 
referred to LLR 
by DHEC for 
potential 
dispensing 
abuse, by 
county 
No, see 
above re: 
prescribers 
See above N/A See above See above See above Review 
RELAES to 
determine 
whether 
this can be 
extracted; 
adopt new 
data entry 
process 
LLR No 
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Policy 
Track 
Measurement Is this 
currently 
measured? 
Does a 
database 
currently 
contain this 
info?  If 
yes, which? 
If currently 
measured, 
baseline 
measurement 
What are 
gaps in 
existing 
data? 
If not 
measured 
how can we 
measure? 
What 
additional 
information is 
necessary for 
an accurate 
measurement? 
Action Steps 
to Improve 
Statistic 
Responsible 
Party 
Legislative 
Action 
Required? 
III. 
Treatment 
1. # of SC 
citizens 
treated 
annually for 
prescription 
drug abuse/ 
addiction (in-
patient and 
OP; adult and 
youthful 
populations). 
Data 
Committee 
suggests 
breaking this 
down into 
public and 
private 
treatment 
centers. 
Yes, for 
public 
facilities 
DAODAS 
and DMH 
have 
information 
about 
public 
facilities;  
RFA has 
info from 
hospitals 
for public 
and private. 
N/A *Billing data 
is available 
for Medicaid 
and State 
Insurance 
Plan, but 
lacks 
uniform 
coding; 
*Billing data 
is built 
around a 
business 
coding 
system, not 
treatment 
*Possible 
midpoint is 
DAODAS 
data; 
*Private 
providers/ 
private 
ambulatory 
treatment 
coding 
system; 
*granularity 
of coding for 
illicit vs. Rx 
drugs 
Establish 
reporting 
criteria 
with caveat 
for gaps 
 Review 
private and 
public 
treatment 
system to 
identify 
possible 
repository 
for needed 
information; 
identify 
strategy for 
uniformity 
RFA (with 
data 
from 
DMH, 
DAODAS, 
HHS, Voc 
Rehab, 
SC State 
Insurance 
Plan) 
WCC? 
Private 
Sources 
Possibly 
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Policy 
Track 
Measurement Is this 
currently 
measured? 
Does a 
database 
currently 
contain this 
info?  If 
yes, which? 
If currently 
measured, 
baseline 
measurement 
What are 
gaps in 
existing 
data? 
If not 
measured 
how can we 
measure? 
What 
additional 
information is 
necessary for 
an accurate 
measurement? 
Action Steps 
to Improve 
Statistic 
Responsible 
Party 
Legislative 
Action 
Required? 
 2. # of 
hospitalizations, 
either ED or 
inpatient 
admissions, 
annually, 
relating to 
prescription 
drug abuse/ 
addiction.  Data 
Committee 
suggests 
“public facility” 
restriction. 
Yes, RFA 
from 
Uniform 
Billing Data 
RFA – 
Uniform 
Billing 
Data 
N/A May not be 
specific as 
to Rx or 
illicit 
Need 
PDAP’s 
restriction 
to public 
facilities so 
that we 
can utilize 
RFA data 
Perhaps EMS 
records 
regarding 
destination, 
but those 
records do not 
reflect 
disposition. 
Review RFA 
data; Identify 
possible 
improvement 
(billing vs. 
treatment 
data); Review 
EMS 
RFA/ 
DHEC 
No 
 3. # of 
treatment 
facilities 
available, by 
county 
Yes DHEC # of centers Unregistered 
facilities 
 All “mom & 
pop” 
operations 
 DHEC No 
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Policy 
Track 
Measurement Is this 
currently 
measured? 
Does a 
database 
currently 
contain this 
info?  If 
yes, which? 
If currently 
measured, 
baseline 
measurement 
What are 
gaps in 
existing 
data? 
If not 
measured 
how can we 
measure? 
What 
additional 
information is 
necessary for 
an accurate 
measurement? 
Action Steps 
to Improve 
Statistic 
Responsible 
Party 
Legislative 
Action 
Required? 
IV. Law 
Enforcement 
1. # of arrests 
(annually) 
attributable to 
prescription 
drugs (DUI, 
diversion, 
possession, 
PWID, theft, 
etc.) 
Yes SLED, 
through 
SCIBRS, 
which 
replaced 
UCR 
Currently, 
“other drugs” 
is global 
category, so 
no baseline 
exists for 
specific Rx 
drugs. 
Need to add 
“special 
circumstances” 
designation to 
be directed by 
PDAP; need 
separate code 
for opiates and 
benzo 
 Designation 
by drug 
Revise SCIBRS 
to add special 
circumstances 
designations 
SLED No 
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Policy 
Track 
Measurement Is this 
currently 
measured? 
Does a 
database 
currently 
contain this 
info?  If 
yes, which? 
If currently 
measured, 
baseline 
measurement 
What are 
gaps in 
existing 
data? 
If not 
measured 
how can we 
measure? 
What 
additional 
information is 
necessary for 
an accurate 
measurement? 
Action Steps 
to Improve 
Statistic 
Responsible 
Party 
Legislative 
Action 
Required? 
 2. # of 
convictions of 
obtaining by 
fraud 
(annually) 
attributable to 
prescription 
drug crimes 
NEED INFO 
FROM 
SOLICITORS/
NCIC 
Each 
Solicitor's 
Office tracks 
dispositions, 
but there is 
no central 
repository 
or 
uniformity. 
N/A There is no 
central 
repository 
with 
uniform 
reporting 
standards. 
A 
centralized 
repository 
can 
facilitate 
this, which 
may 
require 
action by 
Court 
Administra-
tion. 
Centralized 
repository 
Solicitors 
Association 
can work 
toward 
uniform 
reporting 
system. 
Solicitors 
Associa-
tion 
Perhaps, 
for 
allocation 
of 
resources 
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Policy 
Track 
Measurement Is this 
currently 
measured? 
Does a 
database 
currently 
contain this 
info?  If 
yes, which? 
If currently 
measured, 
baseline 
measurement 
What are 
gaps in 
existing 
data? 
If not 
measured 
how can we 
measure? 
What 
additional 
information is 
necessary for 
an accurate 
measurement? 
Action Steps 
to Improve 
Statistic 
Responsible 
Party 
Legislative 
Action 
Required? 
 3. # of 
convictions of 
trafficking 
(annually) 
attributable to 
prescription 
drug crimes 
*Frank 
indicates that 
PWID may be 
better metric 
since there are 
few trafficking 
convictions of 
Rx. 
NEED INFO 
FROM 
SOLICITORS/
NCIC 
Each 
Solicitor's 
Office tracks 
dispositions, 
but there is 
no central 
repository 
or 
uniformity. 
N/A There is no 
central 
repository 
with 
uniform 
reporting 
standards. 
A 
centralized 
repository 
can 
facilitate 
this, which 
may 
require 
action by 
Court 
Administra-
tion. 
Centralized 
repository 
Solicitors 
Association 
can work 
toward 
uniform 
reporting 
system. 
Solicitors 
Associa-
tion 
Solicitors 
Associa-
tion 
 4. # of 
prescription 
drugs seized 
by law 
enforcement 
(by lb.) 
Not 
uniformly; 
SLED gleans 
information 
from incident 
reports, 
which are 
not 
uniformly 
executed. 
No 
common 
repository; 
DEA tracks 
take-back 
days 
Frank to follow 
up with DEA 
contacts 
N/A Lack of 
uniform 
reporting 
Uniform 
reporting by 
all law 
enforcement 
agencies 
Funding 
(fed’l 
grant?) 
SLED can 
initiate 
action with 
locals 
SLED Yes 
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Policy 
Track 
Measurement Is this 
currently 
measured? 
Does a 
database 
currently 
contain this 
info?  If 
yes, which? 
If currently 
measured, 
baseline 
measurement 
What are 
gaps in 
existing 
data? 
If not 
measured 
how can we 
measure? 
What 
additional 
information is 
necessary for 
an accurate 
measurement? 
Action Steps 
to Improve 
Statistic 
Responsible 
Party 
Legislative 
Action 
Required? 
 5. # of take-
back 
programs, by 
county 
NO. This can 
be done 
manually by 
going to each 
county. 
N/A N/A N/A N/A Would have 
to be done 
manually by 
county; need 
a uniform 
tracking 
system 
Funding/ 
training 
SLED 
could be 
repository 
No 
V. Third-
Party 
Payers 
1. Costs to 
government-
provided 
benefit 
programs 
arising from 
prescription 
drug abuse/ 
addiction 
(hospitalization, 
treatment, 
fraud, etc.) 
Yes – Data 
must be 
sorted by 
HHS for 
submission 
to RFA. 
Yes HHS can 
provide. 
N/A N/A N/A Sorting/ 
reporting 
mechanism 
HHS/RFA No 
 2. Costs to 
third-party 
payers arising 
from 
prescription 
drug abuse/ 
addiction 
(hospitalization, 
treatment, 
fraud, etc.) 
PEBA is only 
data set 
currently 
available; 
need help 
from private 
sector 
Yes, but 
we don’t 
have 
access to 
non-PEBA 
N/A Non-PEBA 
data 
Need non-
PEBA data 
Need non-
PEBA data 
Need non-
PEBA data 
RFA for 
PEBA; 
need 
coopera-
tion for 
non-
PEBA 
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Policy 
Track 
Measurement Is this 
currently 
measured? 
Does a 
database 
currently 
contain this 
info?  If 
yes, which? 
If currently 
measured, 
baseline 
measurement 
What are 
gaps in 
existing 
data? 
If not 
measured 
how can we 
measure? 
What 
additional 
information is 
necessary for 
an accurate 
measurement? 
Action Steps 
to Improve 
Statistic 
Responsible 
Party 
Legislative 
Action 
Required? 
 3. #  of 
negative Press 
Gainey scores 
attributable to 
limited access 
to prescription 
drug abuse 
Unknown at 
this time 
        
VI. 
Education 
of the 
Public, 
Patients, 
and 
Providers 
1. Number/ 
Percentage of 
SC youth who 
admit 
inappropriate 
use of 
prescription 
drugs, by 
County (may 
be a % of 
measured 
population) 
Yes, by 
surveys 
conducted in 
alternating 
years by DOE 
and DAODAS 
Yes, 
DAODAS 
and DOE 
Not 
established 
Survey 
participation 
is not 
mandatory, 
so results 
are limited. 
 Mandatory 
participation 
by all schools 
Legislative 
change to 
mandate 
survey 
participa-
tion 
DOE and 
DAODAS 
Yes 
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Policy 
Track 
Measurement Is this 
currently 
measured? 
Does a 
database 
currently 
contain this 
info?  If 
yes, which? 
If currently 
measured, 
baseline 
measurement 
What are 
gaps in 
existing 
data? 
If not 
measured 
how can we 
measure? 
What 
additional 
information is 
necessary for 
an accurate 
measurement? 
Action Steps 
to Improve 
Statistic 
Responsible 
Party 
Legislative 
Action 
Required? 
 2. Percentage 
of licensed 
prescribers 
with controlled 
substance 
registration 
enrolled in 
PMP 
Yes – A 
report can be 
generated 
with the 
number of 
registered 
prescribers. 
PMP has 
the 
number of 
registered 
prescribers; 
LLR has 
number of 
prescribers 
- 24,082 
Total  
(2,907 
Dentists in 
state and 
OOS; 
17,924 
MDs & 
D.O.s; 267 
P.A.s (C2-
5); 486 
P.A.s (C3-
5); 687 
APRNs with 
PA; 1,811 
Vets In 
State & 
OOS 
21% 
Total # of 
unduplicated 
registered 
prescribers 
with BDC to 
include: 
Dentists, MD, 
DO, PA-C, 
APRNs, Vets, 
OD, DPM = 
20,101 
N/A N/A N/A N/A DHEC/ 
LLR 
No 
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Policy 
Track 
Measurement Is this 
currently 
measured? 
Does a 
database 
currently 
contain this 
info?  If 
yes, which? 
If currently 
measured, 
baseline 
measurement 
What are 
gaps in 
existing 
data? 
If not 
measured 
how can we 
measure? 
What 
additional 
information is 
necessary for 
an accurate 
measurement? 
Action Steps 
to Improve 
Statistic 
Responsible 
Party 
Legislative 
Action 
Required? 
 3. # of 
prescribers 
enrolled to 
access PMP 
Yes PMP 4,201 as of 
September 30, 
2014 
N/A N/A N/A N/A DHEC No 
 4. # of patients 
accessed by 
the prescribers 
via PMP 
Not at this 
time 
PMP Not at this 
time 
N/A N/A N/A N/A DHEC No 
 5. # of patients 
counseled (or 
referred for 
rehabilitation) 
by prescribers 
as a result of 
PMP review 
No  N/A See note    DHEC Possibly 
 6. # of 
prescription 
drugs collected 
at take back 
events (by lb.) 
No. See 
discussion 
above re: 
DEA Take-
Back 
programs. 
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Policy 
Track 
Measurement Is this 
currently 
measured? 
Does a 
database 
currently 
contain this 
info?  If 
yes, which? 
If currently 
measured, 
baseline 
measurement 
What are 
gaps in 
existing 
data? 
If not 
measured 
how can we 
measure? 
What 
additional 
information is 
necessary for 
an accurate 
measurement? 
Action Steps 
to Improve 
Statistic 
Responsible 
Party 
Legislative 
Action 
Required? 
 7. # of 
Prescribers 
attending 
Prescription 
Drug Abuse 
Continuing 
Education 
Yes and No LLR 
currently 
tracks CME 
hours, but 
information 
is simply 
scanned in 
and not 
currently 
pulled into 
a database. 
N/A ReLAES does 
not currently 
track specific 
CME 
requirements. 
This can be 
measured 
by linking 
revised 
renewal 
and initial 
applications 
containing 
CME 
certification 
with 
ReLAES. 
Certification 
from 
prescribers re: 
CME 
compliance. 
Modify 
ReLAES and 
applications 
to capture 
this 
information. 
LLR No 
 8. # of 
Prescribers 
Disciplined for 
Prescription 
Drug Abuse 
Prescribing 
Issues 
No LLR has the 
disciplinary 
orders, but 
ReLAES 
does not 
currently 
categorize 
offenses 
with this 
specificity. 
N/A ReLAES 
does not 
currently 
categorize 
offenses 
with this 
specificity. 
ReLAES and 
the order 
processing 
system can 
be revised 
to track 
offenses 
this way. 
N/A Modify 
ReLAES to 
capture this 
information. 
LLR No 
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Policy 
Track 
Measurement Is this 
currently 
measured? 
Does a 
database 
currently 
contain this 
info?  If 
yes, which? 
If currently 
measured, 
baseline 
measurement 
What are 
gaps in 
existing 
data? 
If not 
measured 
how can we 
measure? 
What 
additional 
information is 
necessary for 
an accurate 
measurement? 
Action Steps 
to Improve 
Statistic 
Responsible 
Party 
Legislative 
Action 
Required? 
 9. # of 
Prescribers 
Disciplined for 
Drug Diversion 
Issues 
No LLR has the 
disciplinary 
orders, but 
ReLAES 
does not 
currently 
categorize 
offenses 
with this 
specificity. 
N/A ReLAES 
does not 
currently 
categorize 
offenses 
with this 
specificity. 
ReLAES and 
the order 
processing 
system can 
be revised 
to track 
offenses 
this way. 
N/A Modify 
ReLAES to 
capture this 
information. 
LLR No 
VII. County/ 
Community 
Initiatives 
1. # of 
Counties/ 
Communities 
with Initiative 
to Curb 
Prescription 
Drug Abuse 
*Need 
information 
from 
Michelle 
Nienhius at 
DAODAS 
        
 2. # of 
Hospitals with 
Initiative to 
Curb 
Prescription 
Drug Abuse, by 
County 
*Need to 
obtain 
information 
from SCHA 
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Policy 
Track 
Measurement Is this 
currently 
measured? 
Does a 
database 
currently 
contain this 
info?  If 
yes, which? 
If currently 
measured, 
baseline 
measurement 
What are 
gaps in 
existing 
data? 
If not 
measured 
how can we 
measure? 
What 
additional 
information is 
necessary for 
an accurate 
measurement? 
Action Steps 
to Improve 
Statistic 
Responsible 
Party 
Legislative 
Action 
Required? 
VIII. 
Unintended 
Consequen-
ces 
1. # of deaths 
related to 
heroin 
overdose 
Yes, but not 
uniformly 
WebDeath, 
as 
secondary 
condition 
on Cause of 
Death 
designation 
N/A Not all 
deaths are 
identified 
as heroin 
related; 
Lack of 
uniform 
reporting 
 
Increased 
education and 
training for all 
coroners/ 
medical 
examiners 
Increased 
education 
and training 
for all 
coroners/ 
medical 
examiners 
Coroners 
and 
Individual 
Counties 
Possibly, 
for alloca-
tion of 
resources  
IX. 
Prescriber 
#of Patients 
with > 80 MED 
  52,967 
between  
July 1, 2013, 
and 
September 30, 
2014 
     
*Opioid and benzodiazepine were substituted for the more general word “narcotics” per PDAP Council and Data Committee. 
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OPIATE AND BENZO TOTALS BY COUNTY 
TOTALS for Opiates from 07/01/13 to 06/30/14 
 
TOTALS for Benzo from 07/01/13 to 06/30/14 
COUNTY 
Recipient 
Count 
Rx Count 
Qty 
Dispensed 
  COUNTY 
Recipient 
Count 
Rx Count 
Qty 
Dispensed 
Abbeville 6,503 23,837 1,564,764   Abbeville 2,951 15,086 891,015 
Aiken 39,798 128,343 7,910,699   Aiken 21,693 94,247 5,505,505 
Allendale 2,874 7,670 461,323   Allendale 782 2,759 148,909 
Anderson 52,659 196,383 13,502,000   Anderson 27,025 134,574 8,657,904 
Bamberg 3,639 11,800 676,402   Bamberg 1,530 6,528 392,544 
Barnwell 6,659 21,286 1,398,602   Barnwell 2,973 12,969 790,237 
Beaufort 36,067 101,112 5,064,396   Beaufort 19,700 65,077 3,295,102 
Berkeley 49,831 171,251 10,521,904   Berkeley 20,573 87,976 5,013,172 
Calhoun 3,308 10,256 603,652   Calhoun 1,212 5,837 344,944 
Charleston 86,857 261,507 15,675,050   Charleston 44,271 186,772 10,282,188 
Cherokee 15,770 72,141 5,746,006   Cherokee 7,504 41,172 2,836,422 
Chester 10,736 38,622 2,452,112   Chester 4,272 21,935 1,383,437 
Chesterfield 12,774 52,960 3,682,830   Chesterfield 6,090 32,108 1,853,917 
Clarendon 9,021 31,872 2,146,402   Clarendon 3,123 15,123 974,524 
Colleton 12,631 47,769 3,328,543   Colleton 5,092 22,947 1,424,466 
Darlington 22,668 101,323 8,019,375   Darlington 10,576 57,761 3,705,005 
Dillon 9,490 37,209 2,640,401   Dillon 3,239 15,530 916,172 
Dorchester 38,079 125,789 7,431,890   Dorchester 16,734 72,564 4,000,275 
Edgefield 5,594 16,646 947,392   Edgefield 2,609 11,620 654,390 
Fairfield 6,065 22,079 1,435,833   Fairfield 2,215 10,983 697,094 
Florence 40,760 153,478 10,730,121   Florence 17,129 81,857 4,943,585 
Georgetown 17,340 68,709 4,849,624   Georgetown 7,796 34,864 2,049,160 
Greenville 115,927 385,825 25,545,039   Greenville 54,689 251,963 15,575,267 
Greenwood 19,840 67,185 3,947,973   Greenwood 8,291 38,063 2,201,502 
Hampton 6,032 19,881 1,098,015   Hampton 1,890 8,079 448,048 
Horry 81,426 298,858 21,293,212   Horry 42,371 185,140 10,878,675 
Jasper 6,123 16,910 843,484   Jasper 2,251 7,736 407,964 
Kershaw 16,803 59,185 3,566,440   Kershaw 8,188 40,466 2,404,662 
Lancaster 19,900 65,703 4,008,425   Lancaster 9,020 40,867 2,558,170 
Laurens 20,524 81,404 5,688,014   Laurens 9,230 47,919 3,193,671 
Lee 4,251 14,480 996,511   Lee 1,490 6,800 399,511 
Lexington 73,711 244,344 13,441,412   Lexington 36,076 174,749 10,325,218 
Marion 8,151 34,150 2,568,577   Marion 3,610 18,356 1,157,789 
Marlboro 6,835 29,164 2,183,361   Marlboro 2,510 12,919 739,889 
McCormick 1,947 5,882 345,087   McCormick 745 2,912 170,901 
Newberry 11,182 36,924 2,048,353   Newberry 4,242 19,228 1,131,651 
Oconee 22,891 94,024 7,237,019   Oconee 11,603 57,590 3,903,916 
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TOTALS for Opiates from 07/01/13 to 06/30/14 
 
TOTALS for Benzo from 07/01/13 to 06/30/14 
COUNTY 
Recipient 
Count 
Rx Count 
Qty 
Dispensed 
  COUNTY 
Recipient 
Count 
Rx Count 
Qty 
Dispensed 
Orangeburg 22,421 70,348 4,432,503   Orangeburg 8,171 38,034 2,251,432 
Pickens 33,098 125,075 8,534,608   Pickens 16,440 80,935 5,281,049 
Richland 79,992 220,365 12,234,250   Richland 34,274 145,348 8,418,643 
Saluda 4,427 12,962 642,886   Saluda 1,695 7,756 449,075 
Spartanburg 83,069 325,102 23,243,560   Spartanburg 42,888 217,030 14,080,537 
Sumter 23,994 70,711 4,395,821   Sumter 8,051 35,771 2,100,320 
Union 8,300 37,829 2,883,837   Union 3,992 22,876 1,584,314 
Williamsburg 9,184 31,560 2,044,885   Williamsburg 2,838 13,475 811,382 
York 57,008 161,268 8,805,760   York 26,199 107,157 6,274,824 
TOTAL  1,226,159 4,211,181 272,818,351   TOTAL  569,843 2,611,458 157,508,374 
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